FACULDADE DE ODONTOLOGIA

EFEITOS DOS BISFOSFONATOS NITROGENADOS SOBRE O OSSO

ALVEOLAR

NICOLE DE MELLO RAHDE

2010

PONTIFÍCIA UNIVERSIDADE CATÓLICA DO RIO GRANDE DO SUL

FACULDADE DE ODONTOLOGIA

NICOLE DE MELLO RAHDE

EFEITOS DOS BISFOSFONATOS NITROGENADOS SOBRE O OSSO ALVEOLAR

PORTO ALEGRE

2010

NICOLE DE MELLO RAHDE

EFEITOS DOS BISFOSFONATOS NITROGENADOS SOBRE O OSSO

ALVEOLAR

<div style="margin-left:50%">

Tese apresentada como requisito para obtenção do título de Doutor pelo Programa de Pós-Graduação em Odontologia, Área de Concentração Estomatologia Clínica, Faculdade de Odontologia, Pontifícia Universidade Católica do Rio Grande do Sul

</div>

Orientador(a): Profa. Karen Cherubini

PORTO ALEGRE

2010

Dados Internacionais de Catalogação na Publicação (CIP)

EPÍGRAFE

Uma janela aberta ao conhecimento científico é caminho árduo,
que se percorre com amor à verdade, sabedoria, coragem e
liberdade, com o qual se conquista a paz interior e
o progresso do mundo.

ÉLIDA GOMES TAVARES

(1936 -)

AGRADECIMENTOS

Agradeço à professora **Dra. Karen Cherubini,** cuja sabedoria, coragem e dedicação à ciência são admiráveis. Agradeço pela acolhida carinhosa e comprometimento com o desenvolvimento da Tese. Nesses quatro anos de convívio e amizade, aprendi não só a desenvolver uma pesquisa científica, mas também, que com estudo, empenho e ética, é possível alcançar objetivos aparentemente inatingíveis.

Aos meus pais, **Antonio e Dioneia,** a quem admiro muito e tenho como exemplo de caráter e perseverança. Ambos sempre respeitaram e apoiaram todas as minhas decisões desde muito cedo. Com amor e muito esforço puderam proporcionar a realização dos meus sonhos.

Ao meu irmão **Rafael,** pelo carinho, generosidade e disponibilidade incansáveis em todos os momentos de minha vida em que precisei de ajuda.

À minha irmã **Shalimar,** minha grande companheira, a quem admiro por seu caráter e competência e em quem tento me espelhar. Agradeço o amor e a torcida incondicionais desde sempre.

À minha afilhada **Pietra**, nossa alegria de viver, pelo carinho, companhia e amizade; e por compreender quando não era possível dormir na casa da Dinda.

À minha sobrinha **Manoela**, pelos sorrisos, brincadeiras e intervenções surpreendentes.

Ao **Rodrigo,** por seu amor, paciência e tranquilidade, que serviram de alicerce para a realização desta Tese. Agradeço o carinho, o cuidado, as ideias pertinentes e o interesse real pelo meu trabalho desde que nos conhecemos.

Às professoras do Doutorado em Estomatologia Clínica, **Dra. Liliane Soares Yurgel, Dra. Fernanda Salum e Dra. Maria Antonia Zancanaro de Figueiredo**, pela competência, profissionalismo e ética com que conduzem seu trabalho, além dos inestimáveis ensinamentos transmitidos.

À professora **Dra. Maria Martha Campos** pela constante disposição e ensinamentos fundamentais para a concepção do trabalho.

Ao professor **Dr. Eraldo Batista Jr,** por desvendar os "mistérios" da biologia molecular e pelo trabalho realizado como Presidente da Comissão Científica e de Ética desta Faculdade.

À **Dra. Márcia Maahs,** cujo desprendimento, disponibilidade e participação foram imprescindíveis para a efetivação da presente pesquisa.

Aos colegas do Curso de Doutorado **Aline Morosolli, Carla Girardi, Frederico Saueressig, Juliana Romanini e Tatiana Pinto** pelo companheirismo, apoio mútuo e momentos de descontração.

Ao professor **Marcos Túlio Mazzini Carvalho**, diretor desta Faculdade, por ensinar-nos, desde cedo, a importância da relação paciente/cirurgião-dentista e pelo incentivo constante na busca do aprimoramento profissional.

Ao professor **Dr. José Antonio Poli de Figueiredo**, meu grande Mestre, cuja dedicação pelo que faz foi e sempre será fonte de inspiração e incentivo.

À professora **Dra. Nilza Pereira da Costa** pela disposição e entusiasmo com que conduziu o ensino da Radiologia e a Coordenação da Pós-Graduação.

À professora **Dra. Julieta Tavares**, meu exemplo de profissionalismo, pela amizade de toda a vida, apoio, incentivo, "puxões de orelha" e parceria incansável.

Aos funcionários do Programa de Pós-Graduação em Odontologia **Marcos**, **Ana Lúcia**, **Davenir e Carlos** pela simpatia e competência no trabalho realizado.

À professora **Dra. Edela Puricelli** pelo exemplo profissional e pessoal, que promove a valorização da Odontologia. Agradeço a disponibilidade interminável em transmitir ensinamentos e orientação nas mais diferentes situações.

Aos colegas do Serviço de Odontologia da Santa Casa de Misericórdia de Porto Alegre: **Isabel, Adriana, Gustavo, Baraldi, Mauro, Marcel, Henrique, Jéssica, Vica, Patrícia, Fernanda, Julieta, Clarissa, Mario, Humberto, Liane, Mari, Alessandro, Deise e Letícia**, pela seriedade no trabalho, troca de experiências e espírito de equipe.

Aos colegas do Curso de Especialização em Endodontia da ABO-RS, meus grandes mestres, professores **João Ferlini, Lílian Neuvald Zanatta, Anelise Ligocki, Jussara Mallmann e Régis Burmeister dos Santos,** pelo carinho, convivência alegre e ensinamentos transmitidos desde a graduação até hoje.

Às minhas verdadeiras amigas: **Dani Ody, Deisi, Aninha, Simone, Fernanda Saffer, Fernanda Glitz, Ana Zaffari, Cristiane Pires e Juliana Tigre** pelo apoio e torcida constantes.

A **Angela Rosa de Souza** e a **Carlos Augusto de Souza**, que torceram por mim e souberam compreender minha ausência nos momentos cruciais.

E, enfim, dedico esta Tese aos **pacientes usuários de bisfosfonatos**, que foram acompanhados durante o Curso e inspiraram a realização deste trabalho.

RESUMO

Os bisfosfonatos são drogas inibidoras da reabsorção óssea e têm sido associados a uma forma peculiar de osteonecrose dos maxilares. O efeito dessas drogas é investigado principalmente em tíbia e fêmur, sendo poucos os estudos conduzidos em maxila e mandíbula. A presente pesquisa teve por objetivo investigar, ao exame microscópico, o efeito dos bisfosfonatos nitrogenados alendronato e ácido zoledrônico sobre o osso alveolar. Trinta e um ratos fêmeos (*Rattus norvegicus,* Wistar) foram distribuídos em 3 grupos: (1) 11 animais tratados com alendronato (gavagem oral); (2) 10 animais tratados com ácido zoledrônico (intraperitoneal) e (3) 10 animais que não receberam bisfosfonato. Completado o período de 150 dias do início da terapia, os animais foram submetidos à eutanásia. As maxilas foram processadas e cortes histológicos foram corados por hematoxilina e eosina (HE) e picrossírius. Nos cortes corados por HE, foram realizadas a contagem de osteoclastos e a avaliação da densidade trabecular óssea. Nos cortes corados por picrossírius, a densidade de fibras colágenas dos espaços medulares foi determinada. Também foi realizado processamento imunoistoquímico para avaliação da expressão de osteoprotegerina (OPG). As variáveis foram quantificadas com o auxílio dos programas Adobe Photoshop CS3 e Image Pro Plus 4.5.1. O grupo ácido zoledrônico apresentou densidade trabecular significativamente maior que o grupo-controle (ANOVA, teste de Tukey, *P*<0,001), e o grupo alendronato não apresentou diferença significativa quando comparado aos demais grupos (*P*>0,05). Não houve diferença significativa para contagem de osteoclastos, densidade de fibras colágenas dos espaços medulares e expressão de OPG entre os grupos (ANOVA, *P*>0,05). Os resultados permitem concluir que (1) o ácido zoledrônico promove aumento da densidade trabecular do osso alveolar, enquanto o alendronato não produz esse efeito; (2) alendronato e ácido zoledrônico não estão associados à fibrose dos espaços medulares do osso alveolar. Os efeitos do alendronato e do ácido zoledrônico sobre o número de osteoclastos, bem como sobre a expressão imunoistoquímica de OPG, necessitam ser avaliados por novas pesquisas.

Palavras-chave: Bisfosfonatos, Alendronato, Ácido zoledrônico, Osteonec dos maxilares.

SUMMARY

SUMMARY

Bisphosphonates inhibit bone resorption and have been related to a peculiar form of osteonecrosis of the jaws. Nevertheless, bisphosphonate effects have been investigated mainly in bones like tibia and femur, with just few studies conducted on maxilla and mandible. The present research aimed to investigate bisphosphonates microscopic effects on alveolar bone. Thirty one female rats (*Rattus norvegicus,* Wistar) were allocated into 3 groups: (1) 11 animals treated with oral alendronate; (2) 10 animals treated with intraperitoneal zoledronic acid; and (3) 10 animals without bisphosphonate treatment. One hundred and fifty days after the beginning of the treatment, the animals were euthanized. Maxillae were processed and histological sections were stained with hematoxilin and eosin (H&E) to evaluate bone trabecular density and osteoclast count; and with picrosirius to evaluate collagen fiber density in medullary spaces. Immunohistochemical expression of osteoprotegerin (OPG) was also evaluated. The variables were quantified with Adobe photoshop CS3 and Image Pro Plus 4.5.1 softwares. Zoledronic acid group showed higher trabecular density than control group (ANOVA, Tukey's test, $P<0.001$), and alendronate group did not show significant difference when compared to the other groups ($P>0.05$). There was no significant difference in osteoclast count, collagen fiber density in medullary spaces and OPG expression among the groups (ANOVA, $P>0.05$). According to the results, (1) zoledronic acid promotes trabecular density increase while alendronate does not; (2) alendronate and zoledronic acid use is not associated to alveolar bone marrow fibrosis; (3) alendronate and zoledronic acid effects on osteoclast number and immunohistochemical expression of OPG need to be evaluated by other investigations.

Key-words: Bisphosphonates, Alendronate, Zoledronic acid, Osteonecrosis of the jaws.

SUMÁRIO

SUMÁRIO

INTRODUÇÃO

1. INTRODUÇÃO

Os bisfosfonatos são a mais potente classe de drogas inibidoras da atividade osteoclástica (RUSSELL et al., 2008) e têm como principal indicação o tratamento de enfermidades do metabolismo ósseo, tais como a osteoporose pós-menopausa e induzida por corticoterapia. Também são empregados no manejo de complicações relacionadas a neoplasias, como hipercalcemia maligna, lesões osteolíticas do mieloma múltiplo e metástases ósseas associadas ao câncer de mama, próstata, pulmão e a outros tumores de tecidos moles. Condições menos prevalentes, como a doença de Paget e a osteogênese imperfeita, podem ser igualmente tratadas por essas drogas (MARX, 2007; LANDESBERG et al., 2008; RUGGIERO et al., 2009).

Por serem análogos sintéticos do pirofosfato inorgânico, os bisfosfonatos apresentam alta afinidade por cristais de fosfato de cálcio (hidroxiapatita). Têm como alvo, portanto, a porção mineral do tecido ósseo, sítio em que permanecem por longo período de tempo, e seus efeitos podem persistir por, aproximadamente, dez anos (RUSSELL et al., 2008; MARX; CILLO; ULLOA, 2007). O mecanismo de ação baseia-se na inibição da reabsorção óssea por meio de efeitos diretos e indiretos sobre os osteoclastos. Após a administração, acumulam-se na superfície óssea, em locais de intensa reabsorção, sendo englobados diretamente pelos osteoclastos durante o processo normal de remodelamento. Uma vez no citoplasma da célula, promovem perda de função ou apoptose da mesma, por inibição de sistemas enzimáticos ou produção de metabólitos citotóxicos (SATO et al., 1991; LIN, 1996; ROGERS et al., 2000; THOMPSON et al., 2006; SARIN; de ROSSI; AKINTOYE, 2008). Também inibem a diferenciação das células da linhagem monócito-macrófago em osteoclastos (SAHNI et al., 1993), por meio de alterações da via celular do receptor ativador do fator nuclear κB

(RANK), seu ligante (RANKL) e receptor *decoy* osteoprotegerina (OPG) (VIERECK et al., 2002; PAN et al., 2004; ZHOU et al., 2005). Outros efeitos como inibição da angiogênese (SANTINI et al., 2002; ZERVAS et al., 2006), da proliferação e do reparo tecidual de células epiteliais orais *in vitro* (LANDESBERG et al., 2008), comprometimento da cicatrização da mucosa oral *in vivo* (MAAHS, 2008) e fibrose dos espaços medulares (HANSEN et al., 2006; BEDOGNI et al., 2008) foram relatados.

A osteonecrose maxilar associada ao uso de bisfosfonatos é um efeito adverso dessas drogas e constitui causa de significativa morbidade entre os pacientes acometidos. Para a confirmação diagnóstica da enfermidade, o paciente deve apresentar as seguintes características: tratamento atual ou prévio com bisfosfonatos, exposição do tecido ósseo do complexo maxilo-mandibular ao meio bucal persistente por mais de oito semanas e ausência de história de radioterapia na região de cabeça e pescoço (RUGGIERO et al., 2009). As lesões, geralmente, ocorrem após procedimentos cirúrgicos invasivos nos ossos maxilares, tais como exodontias, colocação de implantes, cirurgias periodontais e periapicais. Casos de exposição óssea espontânea e após trauma causado por próteses parciais removíveis também foram relatados e são atribuídos a características anatômicas e fisiológicas, pois são mais frequentes na região posterior da mandíbula, que apresenta mucosa de espessura fina (MARX et al., 2005; MIGLIORATI; SIEGEL; ELTING, 2006). Os principais sinais e sintomas incluem eritema, edema e ulceração da mucosa, supuração, sequestros ósseos, suscetibilidade à fratura patológica, dor e parestesia. A condição é refratária ao tratamento, e tentativas de debridamento local levam à piora do quadro (RUGGIERO et al., 2004; BAGAN et al., 2005; BAMIAS et al., 2005; MARX et al., 2005; MIGLIORATI; SIEGEL; ELTING, 2006; DUNSTAN; FELSENBERG; SEIBEL, 2007).

Apesar de a osteonecrose maxilar associada ao uso de bisfosfonatos resultar de efeitos recíprocos entre metabolismo ósseo, trauma local, aumento da demanda de reparo ósseo, infecção e hipovascularização (MIGLIORATI et al., 2005), sua patogênese ainda não é completamente conhecida. Além disso, os fatores responsáveis pelo acometimento exclusivo dos ossos maxilares são ignorados (MARX, 2007). A maioria das pesquisas *in vivo* que avaliam os efeitos dos bisfosfonatos são conduzidas em ossos como tíbia e fêmur. A investigação das repercussões microscópicas do uso de bisfosfonatos, especificamente sobre o osso alveolar, se faz necessária para o esclarecimento dessas questões.

O presente estudo compreende dois trabalhos apresentados sob a forma de artigos científicos. O primeiro teve como objetivo fundamentar o experimento por meio de uma revisão da literatura a respeito do mecanismo de ação dos bisfosfonatos e sua relação com a osteonecrose maxilar. O segundo artigo descreve o experimento, cujo objetivo foi investigar, ao exame microscópico, os efeitos dos bisfosfonatos nitrogenados sobre o osso alveolar.

2. ARTIGO 1

O artigo a seguir intitula-se **"Mechanism of action of bisphosphonates and its relation to osteonecrosis of the jaws: A review of the literature"** e foi formatado de acordo com as normas do periódico *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology* (Anexo A).

MECHANISM OF ACTION OF BISPHOSPHONATES AND ITS RELATION TO OSTEONECROSIS OF THE JAWS: A REVIEW OF THE LITERATURE

Nicole de Mello Rahde, DDS, MS.

Fernanda Salum, DDS, PhD.

Maria Antonia Zancanaro de Figueiredo, DDS, PhD.

Karen Cherubini, DDS, PhD.

Porto Alegre, Brazil

PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL

Division of Stomatology and Prevention of Oral and Maxillofacial Cancer, School of Dentistry, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul

Corresponding author:

Karen Cherubini

Serviço de Estomatologia – Hospital São Lucas

Pontifícia Universidade Católica do Rio Grande do Sul

Av Ipiranga, 6690 Sala 231 CEP: 90610-000

Porto Alegre – RS – Brazil

E-mail: karen.cherubini@pucrs.br

    kebini.ez@terra.com.br

Telephone/ fax: +55 51 33203254

Abstract

In the last years, many reports have been published on the occurrence of osteonecrosis of the jaws in patients using nitrogen-containing bisphosphonates who had not had radiotherapy in the craniofacial region. The disease is characterized by non-healing exposure of bone to the oral cavity, associated with pain, paresthesia, suppuration, bone sequestration and susceptibility to pathological fracture. This article addresses chemical features of bisphosphonates, indications and mechanism of action and also reviews one of their major side effects: osteonecrosis of the jaws.

INTRODUCTION

Bisphosphonates are chemical compounds with high affinity for calcium phosphate crystals, exerting their effects on bone tissue. This group of drugs has been widely used in the treatment of diseases of bone metabolism.[1] Their mechanism of action is based on the inhibition of bone resorption and thus of bone remodeling. There are direct and indirect effects on osteoclasts, which undergo apoptosis [2] or become unable to differentiate from hematopoietic stem cells.[3] Impairment of angiogenesis[4] and damage to epithelial cells have also been reported.[5] After administration, bisphosphonates accumulate on the bone surface, at sites of intense resorption, being engulfed by osteoclasts during normal remodeling. They exert intracellular effects, such as loss of function and apoptosis, mediated by the inhibition of enzymatic systems.[1]

Jaws are considered the exclusive site for the occurrence of bisphosphonate-related osteonecrosis.[6] The presence of teeth, which makes the jaws susceptible to bone exposure, along with the high rate of bone turnover, and the need for adequate bone metabolism and blood supply are pointed out as factors responsible for osteonecrosis of

the jaws.[7, 8] However, the factors responsible for the exclusive involvement of the jaws are still unknown.

The purpose of this work was to review the mechanism of action of bisphosphonates and its relation to osteonecrosis of the jaws.

CHEMICAL FEATURES AND INDICATIONS OF BISPHOSPHONATES

Bisphosphonates are considered the most potent class of drugs responsible for the inhibition of osteoclast activity. They have a chemical structure (Fig. 1) similar to that of inorganic pyrophosphate, an endogenous regulator of bone mineralization. The chemical structure is based on the presence of two phosphonate groups linked by phosphoether bonds to a central carbon (a P-C-P structure). The P-C-P structure is resistant to pyrophosphatases and acid hydrolysis. The phosphonate groups provide anchoring to divalent cations such as calcium. They form a three-dimensional structure in a bidentate manner, by coordination of one oxygen from each phosphonate group with the divalent cation. Two additional covalent bonds to the central carbon atom of bisphosphonates form two side chains, R1 and R2. The affinity for the hydroxyapatite can be increased further if one of the side chains (R1) is a hydroxyl or primary amino group, because this allows the formation of a tridentate conformation that is able to bind calcium more effectively.[1, 9] This property explains the long half-life of these drugs in bone tissue, being as long as approximately ten years.[6] R2 components, on the other hand, are responsible for antiresorptive potency, which is magnified in the presence of nitrogen. Thus, nitrogen-containing bisphosphonates (e.g., alendronate, ibandronate, pamidronate, risedronate and zoledronic acid) are more potent than non nitrogen-containing ones (e.g., etidronate, chlodronate and tiludronate).[1, 2, 6, 9, 10]

Fig.1. Bisphosphonate chemical structure (HA= hydroxyapatite).

Bisphosphonates are mainly indicated to treat postmenopausal and corticosteroid-induced osteoporosis, as well as to manage complications related to malignancies, such as hypercalcemia, osteolytic lesions of multiple myeloma, and breast, prostate and lung cancer bone metastases. Off-label use of bisphosphonates has also been reported in Paget's disease and osteogenesis imperfecta.[5, 6, 11] Oral bisphosphonates are generally indicated for the treatment of osteoporosis, where alendronate is the most common followed by risedronate and ibandronate.[6, 12, 13,14] Parenteral bisphosphonate formulations such as zoledronic acid, used once yearly and ibandronate, administered every three months can also be employed for this purpose.[11] The bisphosphonates indicated for the control of hypercalcemia and osteolytic lesions associated with malignancies are administered intravenously. The drug most used in these situations is zoledronic acid followed by pamidronate, both as monthly infusions.[6, 14]

MECHANISM OF ACTION OF BISPHOSPHONATES

The main mechanism of action of bisphosphonates is based on the inhibition of bone resorption and thus of bone remodeling through effects on osteoclasts which undergo apoptosis.[1] An increase in bone mineral density has been demonstrated,[6, 13, 15, 16] since some bisphosphonates such as etidronate, alendronate, pamidronate and olpadronate exert an anti-apoptotic effect on osteoblasts and osteocytes.[1, 17-19]

Direct effects on osteoclasts

After administration, part of the bisphosphonate is available for incorporation into the bone matrix at sites of intense osteoclastic activity.[2] The bisphosphonate remaining is excreted unmetabolized in the urine. Once incorporated into bone tissue, the drug is removed slowly and can remain in place for up to ten years.[20] During resorption, in the acidic environment of the Howship lacuna, bisphosphonate bound to bone is released, the drug reaches high concentrations in solution or in the form of calcium salts, and enters the osteoclast by endocytosis.[1]

Specific intracellular effects occur depending on the presence or absence of nitrogen in the side chain of the molecule. The non nitrogen-containing bisphosphonates are metabolized into cytotoxic analogues of adenosine triphosphate (ATP) and accumulate intracellularly interfering with osteoclast function through inhibition of ATP-dependent enzymes.[6] On the other hand, nitrogen-containing bisphosphonates are considered more potent, and impair the intracellular mevalonate pathway, which is associated with cholesterol biosynthesis. This effect by the latter bisphosphonates occurs through the inhibition of farnesylpyrophosphate synthase, which catalyzes the synthesis of isoprenoid lipids such as farnesylpyrophosphate and geranylgeranyl farnesylpyrophosphate. These molecules modulate prenylation, a structural change of small guanosine triphosphate-binding proteins (GTPases), such as Rhas and Rho. The lack of prenylated protein prevents the anchoring of other molecules of the signaling cascade, causing different changes in cellular function, such as loss of the ruffled border, cytoskeleton breakage, impairment of adhesion proteins and proton pump and inhibition of lysosomal enzymes, as well as apoptosis (Fig.2).[2, 9, 21-23]

Fig. 2. Effects of bisphosphonates on mevalonate pathway, schematic representation. N-BPs inhibit FPP synthase, resulting in lack of prenylated proteins, which are essential to osteoclast activity and survival (N-BPs = nitrogen-containing bisphosphonates; FPP = farnesyl pyrophosphate).

Indirect effects

The mechanism of action of bisphosphonates is not only related to direct actions on osteoclastic activity. Indirect effects, mediated by osteoblasts, have also been observed. Sahni et al.[24] conducted a study in which cells of osteoblast lineage, previously treated with non nitrogen- and nitrogen-containing bisphosphonate for five minutes, were incubated in coculture with untreated osteoclasts attached to a mineral surface (ivory) for 24 hours. There was a decrease in osteoclastic activity resulting in a reduction in the number and diameter of resorption pits. This study was the first to launch the hypothesis that the effects of bisphosphonates on bone resorption also depend on osteoblasts, since they secrete proteins which either stimulate or impair osteoclastogenesis.[3]

RANK/RANKL/OPG pathway

One of the main regulators of the molecular mechanisms involved in the development and function of osteoclasts is the pathway of receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) secreted by osteoblast lineage

cells. OPG is a member of the tumor necrosis factor receptor (TNFR) superfamily and acts as a decoy receptor for RANKL, the osteoclast differentiation-stimulating protein. The binding of RANKL to receptor activator of nuclear factor-κB (RANK) present on the surface membrane of monocyte-macrophage lineage cells, which are osteoclast precursors, produces the signal that leads to their differentiation into osteoclasts. This signal may be interrupted by the secretion of OPG, which binds to RANKL and thereby blocks the interaction with RANK.[6, 25-28]

Some cell culture studies demonstrated an increase in OPG expression in osteoblasts treated with bisphosphonates.[3, 27] Similar results were obtained by Zhou et al.[29] in an *in vivo* study. The authors evaluated OPG immunohistochemical expression in the tibia of mice bearing osteolytic tumors, treated with zoledronic acid. They found increased OPG expression in animals treated with the bisphosphonate in comparison to those that did not receive treatment.

Anti-angiogenic effect

Besides suppressing bone remodeling, bisphosphonates are reported to exert an anti-tumor effect by interfering with angiogenesis. The effect occurs when more potent drugs, such as zoledronic acid, are used. These compounds presumably modulate the secretion of specific growth factors, such as vascular endothelial growth factor (VEGF), and inhibit the proliferation, migration and adhesion of endothelial cells and the consequent formation of capillary tubes.[30, 31] Nevertheless, different results were found by Pampu et al.[32] in rabbits given a single dose of zoledronic acid and submitted 5 days later to mandibular distraction osteogenesis for 5 more days. After 32 days of a consolidation period, a histomorphometric evaluation was performed in the regenerated bone region. Even though it was not statistically significant, there was an increase in the

number of blood vessels. Moreover, Maahs[33] reported that the administration of neither alendronate nor zoledronic acid was associated with lower VEGF immunohistochemical expression in rat maxillae.

Effects on epithelial cells and collagen fibers

Other actions of bisphosphonates have been reported. Deleterious effects on epithelial cells *in vitro*,[5] as well as on oral mucosa healing *in vivo*[33] and increase in fibrous connective tissue (collagen fibers) in medullary spaces of bone tissue[15, 34] were observed.

Landesberg et al.[5] evaluated the effect of pamidronate on oral keratinocytes of mice *in vitro* and found inhibition of cell proliferation and tissue repair when these cells were exposed to therapeutic concentrations of the drug. The effects, however, did not occur at the expense of apoptosis. It is believed that pamidronate promotes necrosis.

BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAWS

There are many cases of bisphosphonate-related osteonecrosis of the jaws (BRONJ) reported in the literature. The condition is characterized by exposed bone in the maxillofacial region that persists for more than eight weeks in patients treated with bisphosphonates who do not have a history of radiotherapy in the head and neck region. The lesions develop spontaneously or after trauma on bone areas covered with a thin mucosal layer or after dento-alveolar surgery.[6, 7, 35] Although a cause and effect relationship has not yet been established, several epidemiological and some experimental studies provide evidence to support a strong correlation between monthly intravenous bisphosphonate therapy associated with tooth extractions, and the development of osteonecrosis.[33, 36] Based on case series, case-control and cohort studies,

the estimated cumulative incidence ranges from 0.8% to 12%. Lower risk is observed with the use of oral bisphosphonates for the treatment of osteoporosis in comparison to intravenous bisphosphonates for the treatment of osteolytic tumors. However, the association of oral bisphosphonate use with co-factors could play a key role in the development of osteonecrosis.[11]

BRONJ is limited to the jaws,[6] since it has not so far been reported in other bones of the skeleton. The factors identified as possible reasons for the uniqueness of the maxilla and mandible in hosting the injury are: (1) the presence of teeth, which exposes bone to the external environment; (2) periodontal disease, abscesses, endodontic treatment as well as the occurrence of injuries[7] requiring bone metabolism and blood supply to maintain the appropriate balance;[37] and (3) the high bone turnover rate at these sites, which causes a higher drug uptake.[8]

Etiopathogenesis

BRONJ is the result of reciprocal complex effects between bone metabolism, local trauma, increased demand for bone repair, infection and hypovascularity.[8] Bone homeostasis depends on the balance between osteoblasts and osteoclasts. When bone resorption is impaired by inhibition of osteoclastic activity, the bone matrix is degraded and non-vital bone, which is characterized by the absence of osteocytes, accumulates.[15] In the jaws, the constant need for repair due to masticatory forces, coupled with the presence of infection when the bone is exposed to the oral environment, increases the demand for resorption to such a level that exceeds the response capacity of the tissue whose metabolism has been modified by bisphosphonates. The result is osteonecrosis.[4,8, 35]

Hansen et al.,[34] using H&E, Grocott and periodic acid-Schiff (PAS), found areas of bone erosion covered with *Actinomyces* sp. in all samples of osteonecrosis from patients receiving bisphosphonates. One sample showed fungi consistent with *Candida* sp. Osteoclasts were observed within resorption lacunae in five out of eight specimens evaluated.

The damage on epithelial cells caused by bisphosphonates, as demonstrated *in vitro* by Landesberg et al.[5], could contribute to the persistent exposure of underlying bone and the development of osteonecrosis.

Clinical features

Clinically, BRONJ occurs as one or multiple areas of alveolar bone exposed to the oral cavity (Fig. 3), which can display sequestration, purulent discharge, ulceration and/or swelling of the adjacent mucosa, fistula or pathological fracture. The patient may have pain or paresthesia; the mandible is more affected than the maxilla, and although less frequently, both bones can be affected simultaneously. The mandibular posterior region is the site of greatest prevalence of osteonecrosis due to compressive forces induced by the occlusion in that area.[6, 7, 11, 20, 37-44]


Fig.3. BRONJ clinical features. (a) 82-year-old male patient under zoledronic acid therapy for multiple myeloma, who developed osteonecrosis at the tooth extraction site; (b) 58-year-old

female patient treated for breast cancer bone metastasis with zoledronic acid, who developed osteonecrosis at implant placement sites.

Imaginological features

The radiographic examination shows ill-defined radiolucent areas in alveolar bone which has a mottled appearance suggestive of osteolytic lesion (Fig. 4) with or without radiopaque areas consistent with bone sequestration. Occasionally, the radiographic signs may be absent.[37, 41, 44] Sclerosis and loss of integrity of the lamina dura (Fig. 4), as well as thickening of the periodontal ligament space could be radiographic signs of subclinical damage caused by bisphosphonates.[6, 7, 11, 45]


Fig. 4. Panoramic radiograph from a female patient under pamidronate therapy, who developed osteonecrosis after extraction of 2nd upper left molar. The black arrow shows osteolytic area in left maxilla; white arrows show sclerosis of lamina dura in lower teeth.

Computed tomography (CT) scans are used to identify alterations difficult to discern on radiographs. They provide three-dimensional information and better delineation of the lesion. Areas of clinically exposed bone in panoramic radiographic images tend to be smaller than the areas of injured bone shown by CT. CT also shows focal sclerosis in early disease with the presence of a disorganized trabecular pattern and poor corticomedullary differentiation.[46]

The findings of magnetic resonance imaging in six patients with a diagnosis of BRONJ showed, in early disease, loss of the normal hyperintensity of fatty marrow in the mandible and maxilla. More advanced BRONJ cases demonstrated bone destruction, soft tissue swelling, inferior alveolar nerve thickening, and pterygoid muscle swelling.[47]

O'Ryan et al.[48] evaluated bone scintigraphy imaging in patients receiving intravenous nitrogen-containing bisphosphonates. They identified positive tracer uptake in maxilla and mandible areas which subsequently developed BRONJ. According to this finding, bone scintigraphy could be useful in the early subclinical detection of BRONJ.

Histological features

On light microscopy, BRONJ appears as multiple areas of non-vital bone, partly confluent, interspersed with residual vital bone. Inflammatory infiltrate, *Actinomyces* sp. colonies and *Candida* sp. are frequent findings.[15, 33, 34, 49] Perinecrotic bone shows inflammatory reaction in the marrow spaces, with marrow fibrosis, inflammatory cell infiltration and blood vessels. Osteoclasts, in contact or not with the bone surface, are also observed.[15, 49]

Sonis et al.,[50] in an animal model of zoledronic acid-related osteonecrosis, found areas of acellular necrotic bone regularly associated with mucosal ulceration and a robust inflammatory response. Proliferation of small blood vessels and absence of *Actinomyces* sp. as determined by PAS staining were also observed.

Risk factors

Based on the latest findings available in the literature, the main risk factors for the development of osteonecrosis is the use of intravenous bisphosphonates and surgical interventions in bone tissue. Other factors related to bisphosphonates, as well as local,

demographic and systemic factors, should also be considered.[10, 11] Drug potency and duration of therapy are directly related to the risk of developing this injury. Zoledronic acid is more potent than pamidronate, which in turn is more potent than oral bisphosphonates.[11]

Local risk factors include dentoalveolar procedures such as tooth extractions, periodontal surgery involving bone, periapical surgery and implant placement. Specific anatomical sites, such as the mylohyoid ridge as well as the maxillary and mandibular *tori*, have a thin mucosa predisposing bisphosphonate users to the development of osteonecrosis. The concomitant presence of inflammatory dental disease such as periodontal and periapical abscesses also increases the risk.[11]

Age and race are demographic factors associated with the risk of developing osteonecrosis. The lesions occur most frequently in older Caucasian patients over 60 years of age. Systemic factors such as renal failure,[11, 51] diabetes,[8, 11] obesity, metastatic disease, low hemoglobin levels,[11] steroids, chemotherapy,[11, 37, 42, 52, 53] smoking[11, 13, 54] and alcohol ingestion[11, 45] can also predispose bisphosphonate users to osteonecrosis.

Treatment

Since the occurrence of the first reports of BRONJ until today, it has not been possible to determine a treatment strategy that promotes the cure of the disease. There is difficulty in obtaining adequate surgical margins, because the entire bone is exposed to bisphosphonate effects. Thus, surgical interventions can often exacerbate the injury. In mild cases, the lesion is controlled by the use of antimicrobial rinses. When there are signs of infection in soft tissues and associated symptoms, systemic antibiotics are used, often for extended periods. Mobile segments of bone sequestration can be removed gently, without exposing uninvolved bone. Elective bone surgery in the maxillofacial

region should be avoided. The other dental procedures that do not involve direct manipulation of bone tissue should be performed in order to prevent the need for tooth extractions.[6, 11]

In some situations, temporary discontinuation of bisphosphonate therapy under the guidance of the attending physician, along with monitoring serum biochemical markers of bone metabolism, may help therapeutic decisions regarding the management of the injury, especially in patients who have taken or are taking oral bisphosphonates.[6]

Hyperbaric oxygen therapy has been evaluated through randomized studies. Preliminary results indicate some improvement in symptoms and partial healing. However, it does not promote the complete repair of the lesions when used as single therapy.[55]

DISCUSSION

Bisphosphonate mechanism of action is based on impairment of bone resorption through direct and indirect effects on osteoclasts.[1] These effects are inhibition of osteoclastogenesis and osteoclastic function, as well as inducing apoptosis of mature cells, causing a reduction in osteoclast number.[2] The role of bone marrow stromal cells or their osteoblast progeny in the maturation of monocyte-macrophage lineage cells into osteoclasts is essential. These precursor cells secrete both RANKL, which stimulates osteoclastogenesis, and OPG, which inhibits it.[56] Bisphosphonates may stimulate OPG secretion and contribute, consequently, to impaired bone resorption, as indicated by some *in vitro*[3, 27] and *in vivo* studies.[29] Anti-angiogenic properties of bisphosphonates were also reported and are associated with anti-tumor activities.[31] However, the consequences of these effects in the jaws are not completely understood. Bisphosphonate actions on the jaws are likely more severe since the high bone turnover

rate in this skeletal region may result in higher drug uptake.[6] The complex microbial flora of the oral cavity associated with the low biological response of bisphosphonate-treated bone leads to several structural changes.[37] Osteonecrosis of the jaws is a serious side effect of bisphosphonates that impairs the quality of life of the patient. The major obstacle lies in the difficulties of developing an adequate therapeutic approach.[11] Furthermore, lack of information among physicians and dentists regarding bisphosphonate mechanism of action and osteonecrosis onset is disturbing, and prevention is still the best strategy available. Not only epidemiological studies, but also experimental investigations, using specific BRONJ animal models, are needed to elucidate aspects that are still obscure.

REFERENCES

1.   Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59.

2.   Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008;14:277-85.

3.   Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-6.

4.   Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.

5.   Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-47.

6.   Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410.

7.   Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.

8.   Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005;104:83-93.

9.   Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78.

10.   Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44:857-69.

11.   Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009;67:2-12.

12.   Dalle Carbonare L, Bertoldo F, Valenti MT, Zenari S, Zanatta M, Sella S, et al. Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 2005;36:645-52.

13.   Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 2007;18:1363-70.

14.   Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-72.

15.   Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:358-64.

16.   Mahl CR, Fontanella V. Evaluation by digital subtraction radiography of induced changes in the bone density of the female rat mandible. Dentomaxillofac Radiol 2008;37:438-44.

17.   Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-37.

18.   Naidu A, Dechow PC, Spears R, Wright JM, Kessler HP, Opperman LA. The effects of bisphosphonates on osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;106:5-13.

19.   Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999;104:1363-74.

20.   Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.

21.   Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85.

22.   Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.

23.   Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006;69:1624-32.

24.   Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11.

25.	Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Biomaterials 2004;25:565-73.

26.	Manolagas SC, Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999;14:1061-6.

27.	Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004;19:147-54.

28.	Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17-25.

29.	Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005;104:1713-20.

30.	Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-4.

31.	Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-3.

32.	Pampu AA, Dolanmaz D, Tuz HH, Avunduk MC, Kisnisci RS. Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits. J Oral Maxillofac Surg 2008;66:905-10.

33.	Maahs MAP. Association between bisphosphonate use and osteonecrosis of the jaws: Study in rats. Dentistry - Post Graduate Program. Porto Alegre: Pontifical Catholic University of Rio Grande do Sul, 2008:89.

34.	Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-60.

35.	Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med 2007;36:319-28.

36.	Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.

37.	Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.

38.   Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3.

39.   Dannemann C, Zwahlen R, Gratz KW. Clinical experiences with bisphopsphonate induced osteochemonecrosis of the jaws. Swiss Med Wkly 2006;136:504-9.

40.   Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, et al. Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Dis 2005;11:365-9.

41.   Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006;17:1512-6.

42.   Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 2006;17:1197-204.

43.   Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15:197-202.

44.   Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.

45.   Agarwala S, Sule A, Pai BU, Joshi VR. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 2002;41:346-7.

46.   Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg 2009;67:75-84.

47.   Krishnan A, Arslanoglu A, Yildirm N, Silbergleit R, Aygun N. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. J Comput Assist Tomogr 2009;33:298-304.

48.   O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg 2009;67:1363-72.

49.   Philippe L, Simon AN, Jean-Pierre C, Brigitte B, Tommaso L, Jean-Pierre W, et al. Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? Bone.

50.   Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 2009;45:164-72.

51.	Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 2006;137:1115-9; quiz 69-70.

52.	Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9.

53.	Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182:417-8.

54.	Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008;66:625-31.

55.	Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67:96-106.

56.	Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.

ARTIGO 2

3. ARTIGO 2

O artigo a seguir intitula-se **"Microscopic and immunohistochemical evaluation of effects of nitrogen-containing bisphosphonates on the rat alveolar bone tissue"** e foi formatado de acordo com as normas do periódico *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology* (Anexo A).

MICROSCOPIC AND IMMUNOHISTOCHEMICAL EVALUATION OF EFFECTS OF NITROGEN-CONTAINING BISPHOSPHONATES ON THE RAT ALVEOLAR BONE TISSUE

Nicole de Mello Rahde, DDS, MSc[a]

Márcia Angélica Peter Maahs, DDS, PhD[a]

Alan Arrieira Azambuja, MSc[b]

Fernanda Salum, DDS, PhD[a]

Maria Antonia Zancanaro de Figueiredo, DDS, PhD[a]

Karen Cherubini, DDS, PhD[a]

Porto Alegre, Brazil

PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL

[a]*Division of Stomatology and Prevention of Oral and Maxillofacial Cancer, School of Dentistry, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul*

[b]*Division of Oncology, School of Medicine, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul*

Corresponding author:

Karen Cherubini

Serviço de Estomatologia – Hospital São Lucas; Av Ipiranga, 6690 Sala 231

CEP: 90610-000; Porto Alegre – RS – Brazil

E-mail: kebini.ez@terra.com.br

     karen.cherubini@pucrs.br

Telephone/ fax: +55 51 33203254

ABSTRACT

Objective. This study aimed to investigate effects of nitrogen-containing bisphosphonates on alveolar bone.

Study design. Thirty-one female Wistar rats were allocated into 3 groups: oral alendronate treatment (n=11); intraperitoneal zoledronic acid treatment (n=10); and control (n=10). After 150 days of treatment, the animals were euthanized, maxillae were processed, and histological sections of alveolar bone were stained with H&E (osteoclast count; trabecular density) and picrosirius (collagen fiber density in medullary spaces). Immunohistochemical expression of osteoprotegerin (OPG) was also evaluated.

Results. Osteoclast count, collagen fiber density and OPG expression were not significantly different between groups. Trabecular density was statistically higher in the zoledronic acid group than control (ANOVA; Tukey; p=0.038), but was not significantly different between alendronate and the other groups.

Conclusions. Zoledronic acid administration increased trabecular density of alveolar bone, while alendronate did not. Neither bisphosphonate tested caused marrow fibrosis; their effects on osteoclast number and OPG expression need further investigations.

INTRODUCTION

Bisphosphonates have been widely used in the treatment of bone metabolism disorders, such as osteoporosis and bone metastases.[1] These therapeutic agents inhibit bone resorption through direct and indirect effects on osteoclasts. After administration, circulating bisphosphonates bind to exposed hydroxyapatite crystals at resorption sites[21] and are engulfed by osteoclasts, exerting intracellular effects.[1] Non nitrogen-containing

bisphosphonates, such as chlodronate, etidronate and tiludronate are metabolized into cytotoxic analogues of ATP, which cause inhibition of osteoclastic activity and apoptosis.[9] Nitrogen-containing bisphosphonates, such as alendronate, risedronate, ibandronate, pamidronate and zoledronic acid, are considered more potent and inhibit the mevalonate pathway. These drugs prevent the formation of prenylated proteins, which regulate a variety of cellular processes involved in osteoclast function. Consequently, loss of osteoclast activity and apoptosis occur.[2, 9, 23]

Indirect effects have also been reported.[1, 24] *In vitro* studies showed that pamidronate[3] and zoledronic acid[3, 27] promoted osteoprotegerin (OPG) secretion by osteoblasts. Immunohistochemical expression of OPG was increased in bone tissue of mice bearing Ewing sarcoma, treated with zoledronic acid.[29] OPG acts as a soluble antagonist for receptor activator of nuclear factor-κB ligand (RANKL), the osteoclast differentiation stimulating protein. When RANKL binds to its receptor RANK on bone marrow mononuclear precursors, they differentiate into osteoclasts. However, when OPG interacts with RANKL, binding to RANK is prevented, and osteoclast differentiation does not occur.[28]

Direct and indirect actions of bisphosphonates reduce the number of osteoclasts available on the bone surface. As a consequence, bone mineral density and trabecular bone density increase.[6, 12, 16] Other effects, such as impairment of both angiogenesis[31] and epithelial cell proliferation,[5] as well as increase in the fibrous component (collagen fibers) of bone medullary space[15, 34] have also been reported.

The occurrence of osteonecrosis of the jaw in patients who have received nitrogen-containing bisphosphonates without history of radiotherapy in the head and neck region has brought concern. The disease is characterized by exposure of bone to the oral cavity, associated with pain, paresthesia, suppuration, bone sequestration and

susceptibility to pathological fracture. The condition is refractory to treatment, since debridement attempts may lead to injury exacerbation.[7, 20, 37, 38, 57]

It is important to consider that the majority of studies evaluating the effects of bisphosphonates on bone have been conducted on the tibia and femur.[58-63] The lack of knowledge about the effects of these drugs on alveolar bone, especially in regard to bone resorption and formation, as well as the restriction of osteonecrosis to the jaws reinforces the need for further investigations.

This study aimed to investigate effects of alendronate and zoledronic acid on the rat alveolar bone tissue, regarding osteoclast number, trabecular bone density, collagen fiber density in medullary spaces and immunohistochemical expression of OPG.

MATERIALS AND METHODS

Animals

The present study was approved by the Ethics Committee of the Pontifical Catholic University of Rio Grande do Sul, and the procedures were carried out in accordance with institutional guidelines for animal care and use. The sample was composed of 31 female Wistar rats (*Rattus novergicus albinus*) aged 140 days and weighing 241 g on average; they were obtained from the animal facility of the Federal University of Pelotas (UFPEL, RS, Brazil). Animals were individually numbered on the tail and housed in plastic cages placed in ventilated racks (Alesco, Monte Mor, SP, Brazil) at a temperature of 22°C with a 12-h light/dark cycle. Animals were fed a standard diet of rat chow (Nuvilab, Colombo, PR, Brazil) and given water *ad libitum*.

No experimental procedures were carried out in the place where the animals were kept to avoid any type of behavioral stress.

Study design

The animals were randomly allocated into three groups, according to the bisphosphonate used: group 1 (n=11): alendronate (0.05 mg/kg, oral gavage, once a week); group 2 (n=10): zoledronic acid (0.6 mg/kg, intraperitoneally, every 28 days); and group 3 (n=10): control (no bisphosphonate used). After completing a period of 150 days of drug administration, the animals were euthanized by inhalation of isoflurane in an appropriate anesthesia chamber[64] (Cristalia, Porto Alegre, RS, Brazil), and the maxillae were removed and fixed in 10% buffered formalin for 24 h. Maxillae were transversally split in the region of the first and second molars, obtaining two fragments, called A and B.

Histological processing

Fragments A and B (n=62) were decalcified in formic acid solution, composed of 780 ml of 10% tribasic sodium citrate P.A. (Cromoline, Diadema, SP, Brazil) and 220 ml of 85% formic acid P.A. (Synth, Diadema, SP, Brazil), for 24 h. They were then paraffin-embedded, cut into 4-µm sections and stained with hematoxylin and eosin (H&E) and picrosirius, as well as submitted to immunohistochemical analysis for OPG detection.

Immunohistochemistry

Antigen retrieval was performed with Tris/EDTA buffer, pH 9 (20 mM Tris/0.65 mM EDTA) in a 99ºC water-bath for 30 min. Endogenous peroxidase was blocked with a 3% solution of hydrogen peroxide in methanol for 30 min. The sections were

incubated in anti-OPG goat polyclonal antibody (SC8468 – Santa Cruz Biotechnology, Santa Cruz, CA, USA), diluted at 1:100. The Dako LSAB kit was used as the detection system. Reaction products were visualized by immersing the sections in 0.03% diaminobenzidine solution containing 0.002% hydrogen peroxide. Hematoxylin was used for counterstaining. Negative control sections were treated identically, except that the primary antibody was substituted with phosphate-buffered saline.

Histological evaluation

The sections were digitized using a light microscope (Olympus BX-50; Olympus America Inc., Miami, FL, USA) coupled to a video camera (CCD-IRIS Sony DXc 107 A/107 AP; Sony, Park Ridge, NJ, USA), with Image Pro Plus 4.5.1 software (Media Cybernetics Inc., Bethesda, MD, USA). The images were analyzed by a calibrated and blinded examiner using Image Pro Plus 4.5.1 and Adobe Photoshop CS3 (Adobe Systems Inc., San Jose, CA, USA) softwares. Intra-examiner agreement was determined with a paired t test ($P<0.05$), Pearson's correlation coefficient and intraclass correlation coefficient, according to the method tested. No significant difference and a strong correlation, as demonstrated by the Pearson correlation coefficient, were observed as follows: trabecular density - $P=$ 0.87, R=0.90; collagen fiber density - P=0.84, R=0.90; and OPG expression - P=0.47; R=0.92. Intraclass correlation coefficient for osteoclast count was R=0.99.

Study endpoints

Osteoclast count

In the H&E stained sections, the number of osteoclasts was determined on the whole extent of alveolar bone surface, from buccal to palatal crest, with a x40 objective.

Large cells containing three or more nuclei located on the bone surface and displaying eosinophilic cytoplasm, were considered osteoclasts (Fig. 1).


Fig.1. Osteoclast count. (a) H&E (40x); black line points out the surface, from buccal (B) to palatal crest (P), where osteoclasts were counted. (b) H&E (400x); osteoclast (arrow) attached to alveolar bone (AB) surface; (PL) periodontal ligament.

Trabecular bone density

Trabecular bone density was evaluated in the H&E sections in four alveolar bone fields (apical, interradicular, buccal and palatal). The histological images were digitized with a x10 objective and analyzed according to Mahl and Fontanella,[16] using Adobe Photoshop CS3 software (Adobe Systems Inc., San Jose, CA, USA). The *extract* filter discarded the structures not corresponding to alveolar bone, and the histogram function calculated total bone area in pixels. The *extract* filter was again used to select only the bone trabeculae, discarding the image of medullary spaces. The histogram function calculated trabecular area (Fig. 2). Trabecular bone density was considered the percentage of trabecular area in each field, calculated using the following formula: trabecular area x 100 / total bone area.

Fig.2. Trabecular density, H&E (x10 objective). (a), (b) Elimination of areas not corresponding to alveolar bone; (c) elimination of image of medullary spaces; (d) trabecular area quantification.

Collagen fiber density in the medullary spaces of alveolar bone

Collagen fiber density in the medullary spaces was evaluated in the picrosirius-stained sections in three bone fields (apical, buccal and palatal), using a x20 objective. Adobe Photoshop CS3 software was used to select only the medullary spaces in each field, with the *extract* filter. The semi-automated segmentation method[65, 66] was used with Image Pro Plus 4.5.1 software (Media Cybernetics Inc., Bethesda, MD, USA) for collagen fiber area quantification. As collagen fibers stained with picrosirius show a red color, the red areas were selected with the function *measure – count/size*. After that, a mask applied to the image converted it into black and white, and the white areas, corresponding to collagen fibers, were quantified in μ^2. The same procedure was performed to quantify total area (Fig. 3). Collagen fiber density was considered the

percentage of collagen area in each field, calculated using the following formula:

collagen area x 100 / total area of medullary spaces.


Fig.3. Collagen fiber density, picrosirius (x20 objective). (a) Medullary spaces previously selected; (b) selection of collagen-positive areas; (c) quantification of collagen-positive areas.

OPG expression

OPG expression was assessed in four alveolar bone fields (apical, interradicular, buccal and palatal), using a x20 objective, with the semi-automated method.[30] Alveolar bone areas expressing OPG showed an intense brown color. The brown areas were selected with the function *measure – count/size*. A mask applied to the image converted it into black and white. The white areas, corresponding to OPG-positive structures, were quantified in μ^2. The same procedure was performed to quantify total area (Fig. 3). Immunohistochemical expression of OPG in alveolar bone was calculated using the following formula: OPG-positive area x 100 / total bone area (Fig. 4).

Fig.4. OPG immunohistochemical expression (x20 objective). (a) *Measure-count/size* function; (b) selection of OPG-positive areas; (c) quantification of OPG-positive areas.

Statistical Analysis

The data were analyzed by descriptive statistics, and the comparison of the variables tested between the three groups was performed using ANOVA and Tukey's test, at a 5% level of significance.

RESULTS

Osteoclast count

Table I displays the results of osteoclast counts in the H&E stained sections of alveolar bone surface. Although the number of osteoclasts was higher in the control group than in alendronate and zoledronic acid groups, there was no statistically significant difference between the three groups analyzed (ANOVA; *P*=0.208). Figure 5 illustrates osteoclast counting on alveolar bone.

Table I: Osteoclast count on alveolar bone surface

Group	Osteoclast number				
	n	Mean	SD	Minimum	Maximum
Alendronate	11	9.09	6.25	0.00	18.00
Zoledronic Acid	10	11.20	5.25	0.00	17.00
Control	10	14.0	9.87	1.00	19.00

SD=Standard deviation; n=Sample size
ANOVA (α=0.05); *P*=0.208

Fig.5. Histological sections showing osteoclast counting (arrows) on alveolar bone surface from (a) alendronate, (b) zoledronic acid and (c) control groups (H&E, 400x).

Trabecular bone density

Regardless of the bone fields evaluated, trabecular density was significantly higher in the zoledronic acid group, when compared to control (ANOVA and Tukey's test; P=0.038). There was no significant difference between the zoledronic acid and alendronate groups, nor between the alendronate and control groups. Regardless of the group evaluated, the apical field showed significantly lower trabecular density when compared to the interradicular, buccal and palatal ones (ANOVA; P<0.001) (Table II; Fig. 6).

Table II: Trabecular density of alveolar bone

Bone field	Group						Total	
	Alendronate		Zoledronic Acid		Control			
	Mean (%)	SD	Mean (%)	SD	Mean (%)	SD	Mean (%)	SD
Apical	91.20	5.13	91.94	3.01	87.67	5.86	90.39[B]	4.97
Interradicular	94.70	5.80	98.07	1.48	95.07	3.22	95.74[A]	4.25
Buccal	98.07	1.18	98.03	1.14	93.57	13.01	96.66[A]	7.33
Palatal	98.85	0.55	98.08	1.40	98.36	0.64	98.46[A]	0.95
Total	95.57[ab]	4.91	96.45[a]	3.30	93.67[b]	8.03	95.27	5.73

SD=Standard deviation
ANOVA; Tukey's test (α=0.05) - Means followed by different upper case letters in the column are significantly different (P<0.001). Means followed by different lower case letters in the row are significantly different (P=0.038).


Fig.6. Histological sections showing alveolar bone trabecular density in (a) alendronate (b) zoledronic acid, and (c) control groups (H&E, 100x).

Collagen fiber density in medullary spaces of alveolar bone

There was no significant difference in collagen fiber density in medullary spaces between the alendronate, zoledronic acid and control groups, nor between the apical, buccal and palatal bone fields (ANOVA; *P*>0.05) (Table III; Fig. 7).

Table III: Collagen fiber density in medullary spaces of alveolar bone

| Bone field | Group | | | | | | Total | |
| | Alendronate | | Zoledronic Acid | | Control | | | |
	Mean(%)	SD	Mean(%)	SD	Mean(%)	SD	Mean(%)	SD
Apical	42.05	10.91	39.88	13.08	37.45	9.11	39.87	10.85
Buccal	50.4	14.17	38.59	11.61	42.75	13.56	44.02	13.45
Palatal	46.72	17.75	45.84	23.84	37.38	8.90	42.96	16.49
Total	45.67	13.99	40.98	15.36	39.06	10.48	41.98	13.38

SD=Standard deviation
ANOVA (α=0.05); *P*>0.05

Fig.7. Histological sections showing collagen fiber in medullary spaces stained by picrosirius (red) in (a) alendronate, (b) zoledronic acid and (c) control groups (picrosirius, 200x).

OPG expression

There was no significant difference in immunohistochemical expression of OPG on alveolar bone between the alendronate, zoledronic acid and control groups (ANOVA; *P*>0.05). Regardless of the group evaluated, the interradicular field demonstrated significantly higher OPG expression than the other fields (ANOVA and Tukey's test; *P*=0.003) (Table IV; Fig. 8).

Table IV: OPG immunohistochemical expression in alveolar bone

Bone field	Group						Total	
	Alendronate		Zoledronic Acid		Control			
	Mean (%)	SD	Mean (%)	SD	Mean (%)	SD	Mean (%)	SD
Apical	11.72	3.90	17.69	9.88	14.64	6.81	14.48 [AB]	7.26
Interradicular	17.21	6.72	19.03	13.69	15.58	4.70	17.15 [A]	8.48
Buccal	8.73	6.10	11.50	6.52	12.12	7.92	10.72 [B]	6.80
Palatal	10.61	4.72	13.32	7.07	11.69	5.11	11.61 [B]	5.32
Total	12.07	6.17	15.34	9.77	13.51	6.25	13.48	7.44

SD=Standard deviation. ANOVA; Tukey's test (α=0.05). Means followed by different letters are significantly different (P=0.003).


Fig.8. OPG expression on alveolar bone detected by immunohistochemistry: (a) alendronate, (b) zoledronic acid, and (c) control group (200x).

DISCUSSION

There was no significant difference in alveolar bone osteoclast count between the three groups analyzed – alendronate, zoledronic acid and control. Lower cell count would be expected in bisphosphonate-treated animals, since apoptosis of mature osteoclasts and suppression of osteoclastogenesis are reported effects of these drugs.[1] Some studies have shown lower osteoclast numbers in mouse bone tissue after bisphosphonate treatment.[58, 61, 63] However, conflicting results regarding this effect of bisphosphonates have been reported in the literature. Kimura et al.[67] and Spolidorio et al.[68] found no significant difference in osteoclast number in the tibia and alveolar bone

between alendronate-treated and untreated animals, which is consistent with the outcome of the present research.

Some points related to the different methods used in each study could explain such discrepancies. The majority of experiments evaluating the effect of bisphosphonates on bone, as in those performed by Ito et al.,[58] Tannehill-Gregg et al.[61] and Zheng et al.,[63] involved the induction of metabolic bone disease before therapy. The results of these studies showed lower osteoclast numbers when bisphosphonates were used. On the other hand, the present investigation and the studies performed by Kimura et al.[67] and Spolidorio et al.[68] evaluated the biological effect of drug administration in normal animals, without a induced disease model. In this situation, no difference in osteoclast number was observed between bisphosphonate and control group. Furthermore, factors such as dosage regimens, treatment duration, type of bisphosphonate and histological techniques are not standardized among experiments. Many studies employ tartrate-resistant acid phosphatase (TRAP), a specific histochemical marker for osteoclasts. When stained by this method, osteoclasts exhibit evident TRAP cytoplasmic activity identified by red staining.[69] The histochemical approach by specifically revealing cells bearing the marker appears to be more reliable than routine histology (H&E), since some osteoclasts, which often displays no nucleus or only one nucleus in histological sections, may go unrecognized during quantification procedures, as well as pre-osteoclasts.[70] However, the decalcification process may cause enzyme denaturation, resulting in a faint or absent stain by this method.[71] Thus, since typical multinucleated osteoclasts are generally easy to identify in routine histology and because this method demonstrates no significant difference in osteoclast number when compared to TRAP staining,[70] H&E was employed in the present study.

Although induction of osteoclast apoptosis would certainly inhibit bone resorption and decrease osteoclast numbers, bisphosphonates might exert other changes in osteoclasts that can also affect their ability to resorb bone. Some of these changes are disruption of osteoclast ruffled border and cytoskeleton, as well as prevention of both lysosomal enzyme release and ATP-dependent proton pump activity.[9] Actually, the initial effect of nitrogen-containing bisphosphonates seems to be impairment of osteoclast function. Eventually, these drugs may cause apoptosis and consequent reduction in osteoclast number, but this event does not appear to be a mandatory requirement for inhibition of resorption by bisphosphonates.[1]

Bisphosphonate action on bone tissue is dose-dependent. Studies have shown that the alendronate dose capable of inducing a decrease in osteoclast number is usually higher than that impairing cell activity.[1] In a previous *in vivo* study,[60] osteoclast number was evaluated after minodronic acid, a potent nitrogen-containing bisphosphonate, was administered to mice with collagen-induced arthritis. Reduction in osteoclast number was only seen in the high-dose minodronic acid group. When a 10-fold lower dose was used, there was no difference in osteoclast number between bisphosphonate and control group. In an *in vitro* study, alendronate inhibited bone resorption in pit assays at doses 10-fold lower than those reducing osteoclast number indicating that the oral bisphosphonate suppression of bone resorption was independent of its effects on apoptosis.[72] It should be noted that the alendronate dose used in the present study was based on the therapeutic dose prescribed for humans and adjusted according to rodents' metabolic rates[73] and to the longer treatment duration (150 days). Whether the calculated dose was only sufficient to promote inhibition of osteoclast function rather than inducing apoptosis requires further investigation.

Moreover, dysfunctional osteoclasts detached from bone surface were found in jaw bone biopsies obtained from areas of diseased but unexposed tissue in patients treated with zoledronic acid, who developed osteonecrosis.[15] This morphological feature indicates inhibition of osteoclast activity by impairment of ruffled border and sealing zone formation, caused by bisphosphonates.[9] Likewise, trans-iliac biopsies from alendronate-treated patients displayed higher osteoclast numbers, when compared to the placebo group. These cells, nevertheless, were detached from bone surface and exhibited pyknotic nuclei,[74, 75] a classic feature of cells undergoing apoptosis.[76] The evaluation of morphological features related to osteoclast activity or apoptosis in the H&E sections was not performed in the present study. Nevertheless, further studies applying this kind of analysis in the same *in vivo* model could disclose those features. Immunohistochemical staining of cellular structures related to osteoclast function, such as ATP-dependent proton pump[58] and methods for detecting cells undergoing apoptosis in histological sections, such as terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) or transmission electron microscopy[76] could address the questions presented here.

There was no significant difference in OPG expression between the alendronate, zoledronic acid and control groups in this research. This result suggests that the bisphosphonates tested did not stimulate OPG secretion in alveolar bone. As a consequence, the crucial signal to drive osteoclast development from hematopoietic progenitor cells would not be inhibited, which is consistent with the lack of effect on osteoclast number in the present study. A similar outcome was reported by Kim et al.[77] with alendronate use, which did not alter RANKL or OPG mRNA expression in mouse osteoblastic cells *in vitro*. Indeed, it has been reported that the mechanism of action of alendronate is not based on impairment of osteoclast recruitment, but on inhibition of

osteoclastic activity.[2] On the other hand, if statistical tests were not considered, the value obtained for OPG in zoledronic acid group would be higher than the other ones (P=0.14). It seems reasonable to consider the possibility of a larger sample size disclosing different results with statistical significance.

Zoledronic acid has been reported to promote an increase in OPG protein secretion by primary human osteoblast-like cells *in vitro*.[3, 27] However, peak plasma levels after intravenous infusion of zoledronic acid are reported to be far lower than that used in *in vitro* experiments. It is uncertain whether the high concentrations used in these studies accurately reflect what occurs in the bone microenvironment *in vivo*.[61] Although a significant increase in OPG expression was not observed at alveolar bone sites of bisphosphonate-treated animals in the present study, it was demonstrated by Zhou et al.[29] In a mouse model of Ewing sarcoma, tibia tissue in zoledronic acid-treated animals showed elevated OPG immunohistochemical expression when compared to untreated animals. Maybe alendronate and zoledronic acid behave differently in alveolar bone when compared to other skeletal sites. The present study showed not only a lack of OPG stimulation but also no changes in osteoclast numbers. Further investigations need to be conducted to resolve this question. In addition, the assessment of RANKL immunohistochemical expression could complement the results obtained. RANKL to OPG ratio is important in the regulation of bone resorption, since the balance between the expression of these two proteins dictates the quantity of bone resorbed.[29, 56]

The zoledronic acid group showed significantly higher trabecular bone density when compared to control group. The alendronate group, on the other hand, showed no statistical difference in trabecular density when compared to the zoledronic acid and control groups. The result concerning zoledronic acid was also reported by other studies in which intravenous bisphosphonate administration increased trabecular density in

bones bearing osteolytic tumors.[78-80] The result concerning alendronate was consistent with the study of Spolidorio et al.,[68] in which the effect of this bisphosphonate was evaluated in alveolar bone of rats without previous disease. In that experiment, no significant difference in trabecular density was found between alendronate and untreated animals, in three alveolar bone regions (buccal, interradicular and palatal). On the other hand, when compared to osteoporosis animal models, the results of the present study were conflicting. Those investigations reported increased trabecular density after oral bisphosphonate use.[12, 59, 81]

Such discrepancies could be explained by the notion that effects of bisphosphonate on bone volume may depend on the rate of bone remodeling before starting treatment. In studies using paired iliac crest biopsies, Borah et al.[82] showed that treatment with an oral nitrogen-containing bisphosphonate for 3 years was associated with an increase in bone volume in patients with high baseline bone turnover compared with no change in this parameter in patients with low baseline turnover. Bisphosphonate uptake in bone depends on hydroxyapatite exposure which occurs in resorption sites. Only the exposed hydroxyapatite is available and accessible to circulating bisphosphonates.[21] Since the animal model employed in the present study and also by Spolidorio et al.[68] did not have high bone turnover induced by any metabolic disease, probably a small amount of hydroxyapatite was exposed. Thus, bisphosphonate uptake and its consequent effects would likely be less prominent in normal animals than in models in which metabolic bone diseases such as osteoporosis were induced.[21] Maybe the lack of association between alendronate and trabecular enlargement was due to a lower uptake of bisphosphonate by the bone tissue because of its normal turnover. Zoledronic acid, on the other hand, promoted trabecular density increase despite the normal bone turnover. The divergent results between the bisphosphonates evaluated

could be explained by the higher mineral affinity of zoledronic acid, related to its three-dimensional molecular configuration and nitrogen disposition.[1]

There was no statistical difference in collagen fiber density in medullary spaces between the groups tested. This fact supports the idea that bisphosphonates *per se* do not promote bone marrow fibrosis. High amounts of fibrous connective tissue in medullary spaces was found in the jaws of patients with bisphosphonate-related osteonecrosis.[15, 34, 39, 49] Actually, marrow fibrosis is a histological feature associated with chronic inflammation in perinecrotic bone.[15, 34, 39, 49] Therefore, the cases of bone marrow fibrosis in patients under bisphosphonate therapy reported are more likely related to the osteonecrosis condition than the bisphosphonate effect.

Comparing the results obtained in each distinct bone field evaluated, there was no significant difference between groups for all variables tested. On the other hand, regardless of the group tested, trabecular density was higher in buccal, palatal and interradicular regions when compared to apical field. This difference, however, was probably due to anatomical and physiological factors related to the animal model and not to the bisphosphonate effects. It should be noted that buccal and palatal fields included the cervical area of the alveolar bone, as the respective crests were considered the initial reference point. Therefore, the results reported here are consistent with the concept that tissue alterations are more evident in cervical regions in maxillary rat molars. In apical sites, the effects are more subtle and show a direct relation to root morphology. Compared to humans, the roots of rats' upper molars are wider in the apical area providing the dissipation of masticatory forces toward the apical region.[83]

Some other aspects on the animal model employed in the present study should also be considered. For screening different therapeutic agents, the rat model has been generally accepted.[84] In fact, the leading preclinical model for osteoporosis is the

ovariectomized rat, in which bisphosphonate therapy is usually tested.[1] Rats' cancellous bone remodeling sites are very similar to those seen in humans, as well as skeleton anatomy.[84] Because of the unique physicochemical properties of bisphosphonates, data from animal studies, especially those related to absorption and deposition, can be reasonably extrapolated to humans.[21]

This study provided relevant evidence about the microscopic effects of oral and parenteral nitrogen-containing bisphosphonates on alveolar bone and showed trabecular enlargement with zoledronic acid use. On the other hand, collagen fiber density in medullary spaces, alveolar bone OPG expression and osteoclast count were not influenced by bisphosphonate administration. Additional studies exploring the balance between RANKL and OPG expression in alveolar bone, as well as the activity of osteoclasts, would contribute to resolving the questions still unanswered.

REFERENCES

1.   Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59.

2.   Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85.

3.   Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78.

4.   Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008;14:277-85.

5.   Thompson K, Rogers MJ, Coxon FP, Crockett JC. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006;69:1624-32.

6.   Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11.

7.   Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Grundker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680-6.

8.   Pan B, Farrugia AN, To LB, Findlay DM, Green J, Lynch K, et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res 2004;19:147-54.

9.   Zhou Z, Guan H, Duan X, Kleinerman ES. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 2005;104:1713-20.

10.   Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17-25.

11.   Dalle Carbonare L, Bertoldo F, Valenti MT, Zenari S, Zanatta M, Sella S, et al. Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 2005;36:645-52.

12.   Mahl CR, Fontanella V. Evaluation by digital subtraction radiography of induced changes in the bone density of the female rat mandible. Dentomaxillofac Radiol 2008;37:438-44.

13.   Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410.

14.   Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-3.

15.   Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839-47.

16.   Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, et al. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:358-64.

17.   Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-60.

18.   Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3.

19.   Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.

20.   Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.

21.   Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.

22.   Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.

23.   Ito M, Amizuka N, Nakajima T, Ozawa H. Bisphosphonate acts on osteoclasts independent of ruffled borders in osteosclerotic (oc/oc) mice. Bone 2001;28:609-16.

24.   Ogawa K, Hori M, Takao R, Sakurada T. Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab 2005;23:351-8.

25.   Tanishima S, Kishimoto Y, Fukata S, Mizumura H, Hagino H, Teshima R. Minodronic acid influences receptor activator of nuclear factor kappaB ligand

expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis. Mod Rheumatol 2007;17:198-205.

26.   Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H, Rosol TJ. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 2006;23:19-31.

27.   Yao W, Balooch G, Balooch M, Jiang Y, Nalla RK, Kinney J, et al. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization. Bone 2006;39:460-9.

28.   Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ, et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 2007;40:471-8.

29.   Close B, Banister K, Baumans V, Bernoth EM, Bromage N, Bunyan J, et al. Recommendations for euthanasia of experimental animals: Part 1. DGXI of the European Commission. Lab Anim 1996;30:293-316.

30.   Amenabar JM, Martins GB, Cherubini K, Figueiredo MA. Comparison between semi-automated segmentation and manual point-counting methods for quantitative analysis of histological sections. J Oral Sci 2006;48:139-43.

31.   Vier-Pelisser FV, Figueiredo MA, Cherubini K, Braga Filho A, Figueiredo JA. The effect of head-fractioned teletherapy on pulp tissue. Int Endod J 2007;40:859-65.

32.   Kimura M, Miyazawa K, Tabuchi M, Maeda H, Kameyama Y, Goto S. Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice. Calcif Tissue Int 2008;82:137-47.

33.   Spolidorio LC, Marcantonio E, Jr., Spolidorio DM, Nassar CA, Nassar PO, Marcantonio RA, et al. Alendronate therapy in cyclosporine-induced alveolar bone loss in rats. J Periodontal Res 2007;42:466-73.

34.   Cerri PS, Boabaid F, Katchburian E. Combined TUNEL and TRAP methods suggest that apoptotic bone cells are inside vacuoles of alveolar bone osteoclasts in young rats. J Periodontal Res 2003;38:223-6.

35.   Baroukh B, Saffar JL. Identification of osteoclasts and their mononuclear precursors. A comparative histological and histochemical study in hamster periodontitis. J Periodontal Res 1991;26:161-6.

36.   Kovacevic M, Tamarut T, Zoricic S, Beslic S. A method for histological, enzyme histochemical and immunohistochemical analysis of periapical diseases on undecalcified bone with teeth. Acta Stomat Croat 2003;37:269-73.

37.   Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001;29:553-9.

38.   Lehman RA, Jr., Kuklo TR, Freedman BA, Cowart JR, Mense MG, Riew KD. The effect of alendronate sodium on spinal fusion: a rabbit model. Spine J 2004;4:36-43.

39.   Jain N, Weinstein RS. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nat Rev Rheumatol 2009;5:341-6.

40.   Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009;360:53-62.

41.   Faloni AP, Sasso-Cerri E, Katchburian E, Cerri PS. Decrease in the number and apoptosis of alveolar bone osteoclasts in estrogen-treated rats. J Periodontal Res 2007;42:193-201.

42.   Kim YH, Kim GS, Jeong-Hwa B. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 2002;34:145-51.

43.   Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.

44.   Daubine F, Le Gall C, Gasser J, Green J, Clezardin P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007;99:322-30.

45.   Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008;68:861-71.

46.   Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis 2005;8:253-9.

47.   Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats. Exp Anim 2006;55:357-67.

48.   Borah B, Dufresne TE, Ritman EL, Jorgensen SM, Liu S, Chmielewski PA, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006;39:345-52.

49.   Dannemann C, Zwahlen R, Gratz KW. Clinical experiences with bisphopsphonate induced osteochemonecrosis of the jaws. Swiss Med Wkly 2006;136:504-9.

50.   Philippe L, Simon AN, Jean-Pierre C, Brigitte B, Tommaso L, Jean-Pierre W, et al. Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? Bone.

51.   Consolaro A, Martins-Ortiz F. Bisphosphonate influence on induced tooth movement and on associated root resorption. In: Consolaro A, editor. Dental resorption in clinical specialties. Maringá: Dental Press; 2005.p.523-69.

52.   Mosekilde L. Assessing bone quality--animal models in preclinical osteoporosis research. Bone 1995;17:343S-52S.

4. DISCUSSÃO GERAL

A osteonecrose maxilar associada ao uso de bisfosfonatos constitui efeito adverso desses fármacos e caracteriza-se, ao exame físico, pela exposição de osso necrótico na cavidade oral. O controle da progressão da doença é a principal estratégia recomendada, uma vez que os procedimentos convencionais não se têm mostrado medidas terapêuticas eficazes (MIGLIORATI; SIEGEL; ELTING, 2006; RUGGIERO et al., 2009). Da mesma forma, a etiopatogênese da condição ainda não foi completamente esclarecida (RUSSELL et al., 2008). Talvez isso ocorra em função de a maioria das publicações basearem-se em observações pontuais de casos clínicos. A literatura prescinde de estudos epidemiológicos longitudinais bem como de investigações experimentais em modelo animal. Tais limitações colaboram para a falta de uma abordagem terapêutica adequada da doença (RUGGIERO et al., 2009).

As dificuldades no manejo dos pacientes que apresentam osteonecrose maxilar associada ao uso de bisfosfonatos inspiraram a concepção e estimularam a realização da presente pesquisa. Os bisfosfonatos mais empregados para o tratamento das complicações de neoplasias osteolíticas e da osteoporose são, respectivamente, o ácido zoledrônico e o alendronato (MARX et al., 2005). A maioria dos estudos analisa a ação dessas drogas em tíbia e fêmur, após a indução de doenças do metabolismo ósseo (TANNEHILL-GREGG et al., 2006; ZHENG et al., 2007). Poucas são as pesquisas que avaliam os efeitos biológicos da administração do ácido zoledrônico e do alendronato no osso alveolar sem a indução de doença óssea prévia. Partindo-se desse pressuposto e considerando-se os relatos da literatura acerca do mecanismo de ação dos bisfosfonatos, importantes variáveis associadas ao efeito desses fármacos sobre o osso alveolar foram investigadas. Ainda, a realização do experimento em modelo animal possibilitou isolar

os fatores a serem estudados e, assim, avaliar a ação dos bisfosfonatos independentemente das variáveis intervenientes que os pacientes, via de regra, apresentam (SONIS et al., 2009).

Os resultados acerca da densidade trabecular obtidos na presente pesquisa corroboram os resultados de outros estudos que relatam o efeito indutor do ácido zoledrônico sobre a formação óssea. O presente estudo demonstrou que, da mesma forma como ocorre em outros ossos do esqueleto (QUINN et al., 2005; DAUBINÉ et al., 2007; MORGAN et al., 2008; RUSSELL et al., 2008), a densidade trabecular aumenta no osso alveolar com o uso do ácido zoledrônico a despeito da ausência de doença metabólica óssea prévia. Em contrapartida, o emprego do alendronato não influenciou significativamente a densidade trabecular do osso alveolar, achado também relatado por Spolidorio et al. (2007). Entretanto, resultados controversos relativos a esse tópico podem ser observados na literatura. Em modelos animais de osteoporose, por exemplo, o emprego do alendronato promoveu aumento da densidade trabecular em tíbia e fêmur (DALLE CARBONARE et al., 2005; OGAWA et al., 2005; IWAMOTO et al., 2006).

Os bisfosfonatos avaliados também não influenciaram a densidade de fibras colágenas dos espaços medulares. Os resultados sugerem que esses fármacos, isoladamente, não sejam os responsáveis pela fibrose medular observada em casos de osteonecrose maxilar associada ao seu uso (BEDOGNI et al., 2008). A ocorrência da fibrose, portanto, parece resultar do processo inflamatório que acompanha a osteonecrose.

O osteoclasto é a célula-alvo dos bisfosfonatos (ROGERS et al., 2000). Esperava-se que essas drogas, por induzirem os osteoclastos à apoptose (ZHENG et al., 2007), viessem a determinar a diminuição da contagem dos mesmos na superfície

alveolar. Entretanto, não foi observado menor número de osteoclastos após o uso de alendronato ou de ácido zoledrônico. Reforçando esse contexto, a expressão imunoistoquímica de OPG também não foi modificada pelo emprego dos medicamentos. Como essa proteína participa do controle da diferenciação osteoclástica, inibindo-a, o aumento da sua expressão contribuiria para a diminuição da contagem dos osteoclastos (KIM et al., 2002) na superfície óssea. Esses resultados são complementares e sugerem que, nas condições da presente pesquisa, os bisfosfonatos não exerceram efeito significativo sobre a osteoclastogênese e sobre a apoptose dos osteoclastos.

O principal efeito dos bisfosfonatos é a inibição da reabsorção óssea (ROGERS et al., 2000). Entre os mecanismos de ação envolvidos nesse processo inibitório, estaria a indução dos osteoclastos à apoptose e consequente diminuição de seu número em cortes histológicos (ROGERS et al., 2000). O fato de, na presente pesquisa, não ter sido observada alteração da contagem de osteoclastos e da expressão de OPG nos grupos-teste reforça a ideia de que a inibição da reabsorção óssea mediada pelo fármaco envolva outros mecanismos além da apoptose dessas células. Talvez o efeito mais relevante da droga no osso alveolar seja a inibição da atividade dos osteoclastos e não a promoção de sua apoptose. Segundo algumas pesquisas realizadas com outros ossos do esqueleto, foi possível observar osteoclastos destacados da superfície óssea, que apresentaram encolhimento do citoplasma e núcleos hipercromáticos após a administração de bisfosfonatos. Tais alterações seriam indicativas da interrupção da atividade celular (ROGERS et al., 2000; BEDOGNI et al., 2008; JAIN; WEINSTEIN, 2009; WEINSTEIN; ROBERSON; MANOLAGAS, 2009). Futuras investigações que avaliem a morfologia e a atividade osteoclástica podem fornecer respostas às questões abordadas. O emprego de marcadores imunoistoquímicos

de estruturas celulares como a bomba de prótons, além de métodos para detectar células em processo de apoptose seriam procedimentos pertinentes.

No contexto atual da osteonecrose maxilar associada ao uso de bisfosfonatos, a prevenção constitui a melhor conduta. A abordagem terapêutica da enfermidade é assunto controverso e apresenta baixa resolutividade, a depender da gravidade do quadro e do fármaco em questão (RUGGIERO et al., 2009). A maioria das pesquisas são desenvolvidas em tíbia e fêmur de modelos animais (ITO et al., 2001; OGAWA et al., 2005; TANNEHILL-GREGG et al., 2006; YAO et al. , 2006; TANISHIMA et al., 2007; ZHENG et al., 2007). Entretanto, existem diferenças anatômicas e fisiológicas entre esses ossos e o complexo maxilomandibular. Esse fato torna-se evidente ao constatar-se a ausência de casos de osteonecrose associada a bisfosfonatos em outros ossos do esqueleto que não maxila e mandíbula (MARX, 2007). Sendo assim, muitos aspectos sobre o mecanismo de ação do fármaco e seus efeitos sobre o osso alveolar permanecem obscuros (RUGGIERO et al., 2009). Novas pesquisas que investiguem interações específicas entre osso alveolar e bisfosfonatos poderão identificar os agentes responsáveis pela exclusividade do complexo maxilo-mandibular em sediar a osteonecrose e, assim, contribuir tanto para a prevenção quanto para nortear uma abordagem terapêutica eficaz da doença.

REFERÊNCIAS

REFERÊNCIAS

AGARWALA, S. et al. Alendronate in the treatment of avascular necrosis of the hip. **Rheumatology**, New York, v. 41, n. 3, p. 346-347, Mar. 2002.

AMENÁBAR, J.M. et al. Comparison between semi-automated segmentation and manual point-counting methods for quantitative analysis of histological sections. **J Oral Sci**, Tokyo, v. 48, n. 3, p. 139-143, 2006.

ARCE, K. et al. Imaging findings in bisphosphonate-related osteonecrosis of jaws. **J Oral Maxillofac Surg,** Philadelphia, v. 67, n. 5, p. 75-84, May 2009.

BAGAN, J.V. et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. **J Oral Pathol Med**, Copenhagen, v. 34, n. 2, p.120-123, Feb. 2005.

BAMIAS, A. et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. **J Clin Oncol**, New York, v. 23, n. 34, p. 8580-8587, Dec. 2005.

BAROUKH, B.; SAFFAR, J.L. Identification of osteoclasts and their mononuclear precursors. A comparative histological and histochemical study in hamster periodontitis. **J Periodontal Res**, Copenhagen, v. 26, n. 3, p. 161-166, May 1991.

BEDOGNI, A. Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod**, Saint Louis, v. 105, n. 3, p.358-364, Mar. 2008.

BOONYAPAKORN, T. et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. **Oral Oncol**, New York, v. 44,n. 9, p. 857-69, Sep. 2008.

BORAH, B. et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. **Bone**, New York, v. 39, n. 2, p. 345-352, Aug. 2006.

CERRI, P.S.; BOABAID, F.; KATCHBURIAN, E. Combined TUNEL and TRAP methods suggest that apoptotic bone cells are inside vacuoles of alveolar bone osteoclasts in young rats. **J Periodont Res**, Copenhagen, v. 38, n. 2, p. 223–226, Apr. 2003.

CONSOLARO, A; MARTINS-ORTIZ, F. Influência dos bisfosfonatos na movimentação dentária induzida e nas reabsorções radiculares associadas. In: CONSOLARO A. **Reabsorções dentárias nas especialidades clínicas.** 2. ed. Maringá: Dental Press, 2005. p. 3-69.

CROTTI, T.N. et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of the receptor activator NFκB, RANK ligand and osteoprotegerin. **Biomaterials**, Guilford, v. 25, p. 565-573, 2004.

DALLE CARBONARE, L. et al. Histomorphometric analysis of glucocorticoid-induced osteoporosis. **Micron**, Oxford, v. 36, n. 7-8, p. 645-652, 2005.

DANNEMANN, C.; GRATZ, K.W.; ZWAHLEN, R. Clinical experiences with bisphosphonate induced osteochemonecrosis of the jaws. **Swiss Med Wkly**, Muttenz, v. 5, n. 136, p. 504-509, Aug, 2006.

DAUBINE, F. et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. **J Natl Cancer Inst**, Cary, v. 99, n. 4, p. 322-330, Feb. 2007.

DUNSTAN, C.R.; FELSENBERG, D.; SEIBEL, M.J. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. **Nat Clin Pract Oncol**, London, v. 4, n. 1, p. 42-55, Jan. 2007.

FALONI, A.P.S. et al. Decrease in the number and apoptosis of alveolar bone osteoclasts in estrogen-treated rats. **J Periodont Res**, Copenhagen, v. 42, n. 3, p.193–201, Jun. 2007.

FREIBERGER, J.J. The utility of hyperbaric oxygen in the treatment of bisphosphonate-related osteonecrosis of the jaws. **J Oral Maxillofac Surg**, Philadelphia, v. 67, n.5, p. 96-106, May 2009.

HALASY-NAGY, J.M.; RODAN, G.A.; RESZKA, A.A. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. **Bone**, New York, v. 29, n. 6, p. 553-559, Dec. 2001.

HANSEN, T. et al. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. **J Oral Pathol Med**, Copenhagen, v. 35, n. 3, p. 155-160, Mar. 2006.

HELLSTEIN, J.W.; MAREK, C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? **J Oral Maxillofac Surg**, Philadelphia, v. 63, n. 5, p. 682-689, May 2005.

HEWITT, C.; FARAH, C.S. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review. **J Oral Pathol Med**, Copenhagen, v. 36, n. 6, p. 319-328, Jul. 2007.

ITO, M. et al. Bisphosphonate acts on osteoclasts independent of ruffled borders in osteosclerotic (oc/oc) mice. **Bone**, New York, v. 28, n. 6, p. 609-616, Jun. 2001.

IWAMOTO, J. et al. Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats. **Exp Anim**, Tokyo, v. 55, n. 4, p. 357-367, 2006.

JAIN, N.; WEINSTEIN, R.S. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. **Nat Rev Rheumatol**, New York, v. 5, n. 6, p. 341-346, Jun. 2009.

KHOSLA, S. et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. **J Bone Miner Res**, Washington, v. 22, n. 10, p. 1479-1491, Oct. 2007.

KIM, Y.H.; KIM, G.S.; JEONG-HWA, B. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. **Exp Mol Med**, Seoul, v. 34, n. 2, p. 145-151, May 2002.

KIMURA M. et al. Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice. **Calcif Tissue Int**, New York, v. 82, n. 2, p. 137-147, Feb. 2008.

KOVACEVIC, M. et al. A method for histological, enzyme histochemical and immunohistochemical analysis of periapical diseases on undecalcified bone with teeth. **Acta Stomat Croat**, v.37, n. 3, p. 269-273, 2003.

KRISHNAN, A. et al. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. **J Comput Assist Tomogr**, Hagerstown, v. 33, n.2, p. 298-304, Feb. 2009.

KYLE, R.A. et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. **J Clin Oncol**, New York, v. 10;25, n. 17, p. 2464-2472, Jun. 2007.

LANDESBERG, R. et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. **J Oral Maxillofac Surg**, Philadelphia, v. 66, n. 5, p. 839-847, May 2008.

LEHMAN, A. et al. The effect of alendronate sodium on spinal fusion: a rabbit model. **Spine J**, New York, v. 4, n.1, p. 36–43, Jan-Feb. 2004.

LIN, J.H. Bisphosphonates: a review of their pharmacokinetic properties. **Bone**, New York, v. 18, n. 2, p. 75-85, Feb. 1996.

MAAHS, M. **Associação entre o uso de bisfosfonatos e osteonecrose dos maxilares: estudo em ratos.** Tese – Faculdade de Odontologia da PUCRS, Porto Alegre, 2008. 87p.

MAHL, C.R.; FONTANELLA, V. Evaluation by digital subtraction radiography of induced changes in the bone density of the female rat mandible. **Dentomaxillofac Radiol**, Tokyo, v. 37, n. 8, p. 438-444, Dec. 2008.

MANOLAGAS, S.C.; WEINSTEIN R. S. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. **J Bone Miner Res**, Washington, v. 14, n. 7, p. 1061-1066, Jul.1999.

MANOLAGAS, S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. **Endocr Rev**, Baltimore, v. 21, n. 2, p. 115-137, Apr. 2000.

MARX, R.E. et al. Bisphosphonate - Induced Exposed Bone (Osteonecrosis / Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. **J Oral Maxillofac Surg**, Philadelphia, v. 63, n. 11, p. 1567-1575, Nov. 2005.

MARX, R.E. **Oral & intravenous bisphosphonate – induced osteonecrosis of the jaws. History, etiology, prevention and treatment**. Chicago:Quintessence; 2007. 150p.

MARX, R.E.; CILLO, J.E.; ULLOA, J.J. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. **J Oral Maxillofac Surg**, Philadelphia, v. 65, n. 12, p. 2397-2410. Dec. 2007.

MIGLIORATI, C.A. et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. **J Am Dent Assoc**, Chicago, v. 136, n. 12, p. 1658-1668, Dec. 2005.

MIGLIORATI, C.A.; SIEGEL, M.A.; ELTING, L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. **Lancet Oncol**, London, v. 7, n. 6, p. 508-514, Jun. 2006.

MORGAN, T.M. et al. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. **Prostate**, New York, v. 68, n. 8, p. 861-871, Jun. 2008.

MOSEKILDE L. Assessing bone quality-animal models in preclinical osteoporosis research. **Bone**, New York, v. 17, n. 4, p.343S-352S, Oct. 1995.

NAIDU, A. et al. The effects of bisphosphonates on osteoblasts in vitro. **Oral Surg Oral Med Oral Pathol Oral Radiol Endod**, Saint Loius, v. 106, n. 1, p. 5-13, Jul. 2008.

NASE, J.B.; SUZUKI, J.B. Osteonecrosis of the jaw and oral bisphosphonate treatment. **J Am Dent Assoc**, Chicago, v. 137, n. 8, p. 1115-1119, Aug. 2006.

OGAWA, K. et al. Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. **J Bone Miner Metab**, Tokyo, v. 23, n. 5, p. 351-358, 2005.

O'RYAN, F.S. et al. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. **J Oral Maxillofac Surg**, Philadelphia, v. 67, n. 7, p. 1363-1372, Jul. 2009.

PAMPU, A.A. et al. Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits. **J Oral Maxillofac Surg**, Copenhagen, v. 66, n. 5, p. 905-910, May. 2008.

PAN, B. et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-α converting enzyme (TACE). **J Bone Miner Res**, Washington, v. 19, n. 1, p. 147-154, 2004.

PHILIPPE, L. et al. Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? **Bone**, New York, *In Press*, 2009.

PIRES, F.R. et al. Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. **Oral Dis**, London, v. 11, n. 6, p. 365-369, Nov. 2005.

PLOTKIN, L.I. et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. **J Clin Invest**, Ann Arbor, v. 104, n. 10, p. 1363-1374, Nov. 1999.

PURCELL, P.M.; BOYD, L.W. Bisphosphonates and osteonecrosis of the jaw. **The Med J Aust**, Sidney, v. 182, n. 8, p. 417-418, Apr. 2005.

QUINN, J.E. et al. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. **Prostate Cancer Prostatic Dis**, London, v. 8, n. 3, p. 253-259, 2005.

ROGERS, M.J. et al. Cellular and molecular mechanisms of action of bisphosphonates. **Cancer**, Hoboken, v. 15;88, n. 12, p. 2961-2978, Jun. 2000.

RUGGIERO, S.L. et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. **J Oral Maxillofac Surg**, Philadelphia, v. 62, n. 5, p. 527-534, May 2004.

RUGGIERO, S.L. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. **J Oral Maxillofac Surg**, Philadelphia, v. 67, n. 5, p. 2-12, May 2009.

RUSSELL, R.G. et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. **Osteoporos Int**, London, v.19, n. 6, p. 733-759, Jun. 2008.

SAHNI, M. et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. **J Clin Invest**, Ann Arbor, v. 91, n. 5, p. 2004, 2011, May 1993.

SANNA, G. et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. **Ann Oncol**, Oxford, v. 17, n. 10, p. 1512-1516, Oct. 2006.

SANTINI, D. et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. **Clin Cancer Res**, Philadelphia, v. 8, n. 5, p.1080-1084, May. 2002.

SARIN, J.; DEROSSI, S.S.; AKINTOYE, S.O. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. **Oral Dis**, Copenhagen, v. 14, n.3, p.277-285, Apr. 2008.

SATO, M. et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclasts ultrastructure. **J Clin Invest**, Ann Arbor, v. 88, n. 12, p. 2095-2105, Dec. 1991.

SONIS, S.T. et al. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. **Oral Oncol**, New York, v. 45, n. 2, p. 164-72, Apr. 2009.

SPOLIDORIO, L.C. et al. Alendronate therapy in cyclosporine-induced alveolar bone loss in rats. **J Periodontal Res**, Copenhagen, v. 42, n. 5, p. 466-473, Oct. 2007.

TANISHIMA, S. et al. Minodronic acid influences receptor activator of nuclear factor kB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis. **Mod Rheumatol**, Tokyo, v. 17, n. 3, p. 198–205, Jun. 2007.

TANNEHILL-GREGG, S.H. et al. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. **Clin Exp Metastasis**, London, v. 23, n.1, p. 19-31, May 2006.

TEITELBAUM, S.L. Bone resorption by osteoclasts. **Science**, Washington, v. 289, n. 5484, p. 1504-1508, Sep. 2000.

THOMPSON, K. et al. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. **Mol Pharmacol**, Bethesda, v. 69, n. 5, p.1624-1632, May 2006.

van den WYNGAERT, T.; HUIZING, M.T.; VERMOKEN, J.D. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? **Ann Oncol**, Oxford, v. 17, n. 8, p. 1197-1204, Aug. 2006.

VIERECK, V. et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. **Biochem Biophys Res Commun**, San Diego, v. 291, n.3, p. 680–686, Mar. 2002.

VIER-PELISSER, F.V. et al. The effect of head-fractioned teletherapy on pulp tissue. **Int Endod J**, Oxford, v. 40, n.11, p. 859-865, Nov. 2007.

WADA, T. et al. RANKL–RANK signaling in osteoclastogenesis and bone disease. **Trends Mol Med**, Oxford, v. 12, n. 1, p. 17-25, Jan. 2006.

WALTER, C. et al. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. **Support Care Cancer**, Berlim, v. 15, n. 2, p. 197-202, Feb. 2007.

WEINSTEIN, R.S.; ROBERSON, P.K.; MANOLAGAS, S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. **N Engl J Med**, Boston, v. 360, n.1, p. 53-62, Jan. 2009.

WESSEL, J.H.; DODSON, T.B.; ZAVRAS, A.I. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. **J Oral Maxillofac Surg**, Philadelphia, v. 66, n. 4, p. 625-631, Apr. 2008.

WOO, J.S.; HELLSTEIN, J.W.; KALMAR, J.R. Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws. **Ann Int Med,** Philadelphia, v. 16, n. 10, p. 753-761, May, 2006.

WOOD, J. et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. **The Journal of Pharmacology and Experimental Therapeutics**, Baltimore, v. 302, n. 3, p. 1055-1061, Apr. 2002.

YAO, W. et al. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization. **Bone**, New York, v. 39, n. 3, p. 460–469, Sep. 2006.

YAROM, N. et al. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. **Osteoporos Int**, London, v. 18, n. 10, p. 1363-1370, Oct. 2007.

ZERVAS, K. et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. **Br J Haematol**, Oxford, v. 134, n. 6, p. 620-623, Sep. 2006.

ZHENG, Y. et al. Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. **Bone**, New York, v. 40, n. 2, p. 471–478, Feb. 2007.

ZHOU, Z. et al. Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. **Cancer**, Hoboken, v. 104, n. 8, p. 1713-1720, Oct. 2005.

ANEXOS

ANEXO A

De: ees.tripleo.0.5a1f2.74eb337c@eesmail.elsevier.com em nome de Editor-in-Chief TripleO
Enviada: sex 11/12/2009 19:53
Para: kebini.ez@terra.com.br; Karen Cherubini
Assunto: Submission Confirmation

Dear Dr. Cherubini,

Your submission entitled "MECHANISM OF ACTION OF BISPHOSPHONATES AND ITS RELATION TO OSTEONECROSIS OF THE JAWS: A REVIEW OF THE LITERATURE" has been received by Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology.

You may check on the progress of your paper by logging on to the Elsevier Editorial System as an author. The URL is http://ees.elsevier.com/tripleo/.

Your manuscript will be given a reference number once an Editor has been assigned.

Thank you for submitting your work to this journal.

Kind regards,

Elsevier Editorial System
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

De: ees.tripleo.0.5a813.8a4baee8@eesmail.elsevier.com em nome de Editor-in-Chief TripleO
Enviada: sáb 12/12/2009 22:01
Para: kebini.ez@terra.com.br; Karen Cherubini
Assunto: Submission Confirmation

Dear Dr. Cherubini,

Your submission entitled "MICROSCOPIC AND IMMUNOHISTOCHEMICAL EVALUATION OF EFFECTS OF NITROGEN-CONTAINING BISPHOSPHONATES ON THE RAT ALVEOLAR BONE TISSUE" has been received by Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology.

You may check on the progress of your paper by logging on to the Elsevier Editorial System as an author. The URL is http://ees.elsevier.com/tripleo/.

Your manuscript will be given a reference number once an Editor has been assigned.

Thank you for submitting your work to this journal.

Kind regards,

Elsevier Editorial System
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

ANEXO B

Editorial Office

Publisher

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology On-Line Manuscript Submission

Submission of Manuscripts. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology* uses an online, electronic submission system. By accessing the website http://ees.elsevier.com/tripleo authors are stepwise through the creation and uploading of the various files. When submitting a manuscript to the Elsevier Editorial System (EES), authors <u>must</u> provide an electronic version of their manuscript. For this purpose original source files, not PDF files, are required. The author should specify an article type for the manuscript (full length article, review article, case report, etc.), choose a set of classifications from the prescribed list provided online, and suggest the appropriate Journal section. Authors may send queries concerning the submission process, manuscript status, or Journal procedures to the Editorial Office. Once the submission files are uploaded, the system automatically generates an electronic (PDF) proof, which is then used for reviewing. All correspondence, including the Editor's decision and request for revisions will be communicated by e-mail.

International authors who are not completely fluent in the English language should seek help in the preparation of their manuscripts. Such assistance will enhance the review, improve the chance of acceptance, and greatly reduce the time until publication if the article is accepted.

If your manuscript is accepted, the Editors reserve the right to determine whether it will be published in the print edition or solely in the Internet edition of the Journal. Articles accepted for publication are subject to editorial revision.

Statements and opinions expressed in the articles and communications herein are those of the author(s) and not necessarily those of the Editor(s) or publisher, and the Editor(s) and publisher disclaim any responsibility or liability for such material. Neither the Editor(s) nor the publisher guarantees, warrants, or endorses any product or service advertised in this publication. Neither do they guarantee any claim made by the manufacturer of such product or service.

Duality of Interests. Any commercial or other associations that might create a duality of interests in connection with a submitted manuscript must be disclosed. All sources of external funds supporting the work must be indicated in a footnote, as should all corporate affiliations of the authors including author(s) relationship with a corporate entity involved with the subject of the research or product being espoused in

the submission. A cover letter at the time of submission should inform the Editor of pertinent consultancies, stock ownership or other equity interests, or patent licensing arrangements. All information will remain confidential while the paper is being reviewed and will not influence the editorial decision. If the manuscript is accepted, the Editor will communicate with the authors how best to disclose the relevant information.

Publication Standards of Ethical Conduct. Submitting manuscripts for publication that contain elements of fabrication, falsification, or plagiarism constitutes a major violation of the universally accepted standards of ethical and scientific conduct.

Articles falling into the following categories are invited for submission:

Review manuscripts. Manuscripts that review the current status of a given topic, diagnosis, or treatment are encouraged. These manuscripts should not be an exhaustive review of the literature, but rather should be a review of contemporary thought with respect to the topic. Likewise, the bibliography should not necessarily be all-inclusive but rather include only seminal, pertinent, and contemporary references deemed to be most important by the author.

Clinicopathologic Conference. Papers submitted for the Clinicopathologic Conference (CPC) should present interesting, challenging, or unusual cases. The presentation should simulate clinical work-up, including a differential diagnosis. The complete diagnostic evaluation, management, and follow-up must be included. CPC articles will be organized into five parts: *Clinical presentation*-describe the clinical and imagining characteristics of the lesion. Use clinical photographs and radiographs as appropriate. *Differential diagnosis*-list and discuss lesions to be considered as reasonable diagnostic possibilities. *Diagnosis*-histopathologic findings illustrated with photomicrographs.*Management*-describe the treatment of the patient and response to treatment. *Discussion*-concentrate on the most interesting aspect(s) of the case.

Medical Management and Pharmacology Update. The Medical Management and Pharmacology Update (MMPU) is intended to provide concise, current reviews of medical problems and how they relate to dentistry. Manuscripts should include a good review of the clinical aspects of the disease, stressing the impact of the disease on the dental management and dental treatment of the patient. Emphasis should be placed on new developments, new research, or new approaches to therapy or management. Manuscripts should not be an exhaustive review of the literature, but rather a review of contemporary thought with respect to the topic. Likewise, the bibliography need not be all inclusive but rather should include only seminal, contemporary references deemed by the author to be most pertinent. The desired format for manuscripts submitted for the MMPU would include: an abstract; topic introduction/overview; epidemiology/demographics; etiology and pathogenesis; clinical presentation/physical findings; diagnosis (laboratory tests, diagnostic imaging, etc.); medical management and treatment; complications; prognosis; oral manifestations/dental implications and significance; and dental management (of patients with the disease). Manuscripts should not exceed 12 pages in 12 point, double-spaced Times New Roman (Tables and Figures count toward the 12-page limit).

Pharmacology Update is a component section of MMPU that offers the reader the opportunity to obtain concise information regarding drugs used in the practice of medicine, clinical dentistry and dental specialties. Papers submitted should present clearly and concisely background information regarding the disease or condition that is managed, the indications, rational and approved uses of the specific drugs or class of drugs, the advantages and benefits of the drug or drug class over previous drugs, mechanism of action, criteria for selection, usual dosage, pharmacokinetics, adverse effects, drug interactions, and oral health and dental management considerations. Emphasis should be placed on new developments, effectiveness in clinical trials, therapeutic outcomes and safety. Manuscripts should reflect the contemporary thought with respect to the topic. Use of figures to illustrate the mechanism of action, and tables to presents therapeutic outcomes, drug interactions, and adverse effects are encouraged. Manuscripts should utilize the above mentioned categories for formatting the paper. Papers should not exceed 3000 words. The recommended font is 12 point, double spaced Times New Roman. A maximum of 50 references is recommended.

Clinical Notes. The Clinical Notes feature is intended to provide a forum for brief communications of a technical nature.They are not scientific papers; they may report a new instrument, technique, procedure, or, in rare situations, an interesting case report.

Copyright statement. The specified copyright statement that follows the Information for Authors in each issue of the Journal must be completed, **signed by all authors**, and faxed to the Editorial Office at (601)984-4949. If not completed in full, it will be returned to the author for completion. The copyright statement may be photocopied for submission or scanned and e-mailed.

Copyright statement. The copyright-transfer document must be downloaded, completed, signed by the responsible author, scanned and attached as a file in the submission process.

Preparation of manuscripts. Only original manuscripts that have not been published in other forms will be considered for publication. Correct preparation of the manuscript by the author will expedite the reviewing and publication procedures. Manuscripts should be word processed double-spaced. Please note the following requirements and the instructions for online submission at http://ees.elsevier.com/tripleo .

The article, including all tables, should be formatted in the latest version of Microsoft Word. The use of appropriate subheadings throughout the body of the text (Methods, Results, and Discussion sections) is required. Legends for figures and tables should appear after the reference list. If an illustration has been taken from published material, the legend must give full credit to the original source. Illustrations must also be submitted electronically as separate files (not embedded). File specifications are listed below in "Illustrations." Tables should be submitted as separate files (in Microsoft Word (*.doc) format.)

Routine case reports add little to our knowledge, but good case reports may occasionally be published if they meet certain criteria: (1) are of rare or unusual lesions that need documentation, (2) are well documented cases showing unusual or "atypical" clinical or microscopic features or behavior, or (3) are cases showing good long-term follow-up information, particularly in areas in which good statistics on results of treatment are needed.

Title Page. The title page of the manuscript should include the title of the article, the full name of the author(s), academic degrees, positions, and institutional affiliations. Listed authors should include only those individuals who have made a significant creative contribution. The corresponding author's address, business and home telephone numbers, fax number and e-mail address should be given.

Authorship. All persons who are identified as authors must have made substantial contribution to the manuscript through significantly contributing to the conception, design, analysis or interpretation of data; drafting or significantly revising the manuscript; and providing final approval of the manuscript. All three of these conditions must be met by each author. Persons who contribute to the effort in supporting roles should not be included as authors; rather they should be acknowledged at the end of the paper.

Abstract. An abstract of no more than 150 words, typewritten double-spaced, should precede the introduction to the article and must accompany each manuscript.

Structured abstract. A structured abstract limited to 150 words must be used for data-based research articles. The structured abstract is to contain the following major headings: *Objective(s); Study Design; Results; and Conclusion(s).* The *Objective(s)* reflects the purpose of the study, that is, the hypothesis that is being tested. The *Study Design* should include the setting for the study, the subjects (number and type), the treatment or intervention, and the type of statistical analysis. The *Results* include the outcome of the study and statistical significance if appropriate. The *Conclusion(s)* states the significance of the results.

Methods. The methods section should describe in adequate detail the experimental subjects, their important characteristics, and the methods, apparatus, and procedures used so that other researchers can reproduce the experiment. When the paper reports experiments on human subjects, the methods section must indicate that the protocol was reviewed by the appropriate institutional review board (IRB) and that each subject in the project signed a detailed informed consent form.

Animals. Please indicate that protocols were reviewed by the appropriate institutional committee with respect to the humane care and treatment of animals used in the study.

References. References should be cited selectively. Personal communications and unpublished data are not to be cited as references; instead, are to be cited in parentheses at the appropriate place in the text. Make sure all references have been verified and are cited consecutively in the text (not including tables)

by superscript numbers. Reference list format must conform to that set forth in "Uniform Requirement for Manuscripts Submitted to Biomedical Journals" (Ann Intern Med 1997;126:36-47). A copy of these Requirements may be viewed/printed online at www.icmje.org. References to articles in press must include authors' surnames and initials, title of article, and name of journal. The reference list should be typed double-spaced on a separate page and numbered in order as the reference citations appear in the text. For journal citations, include surnames and initials of authors, complete title of article, name of journal (abbreviated according to the Cumulated Index Medicus), year of publication, volume, number, and inclusive page numbers. For book citations, surnames and initials of authors, chapter title (if applicable), editors' surnames and initials, book title, volume number (if applicable), edition number (if applicable), city and full name of publisher, year of publication, and inclusive page numbers of citation.

EXAMPLES (if six or fewer authors, list all; if seven or more list first six and add *et al*):

Format for periodical references: Pullon PA, McGivney J. Computer utilization in an oral biopsy service. Int J Oral Surg 1977;6:251-5.

Format for book references: Seakins J, Saunders R, editors. Treatment of inborn errors of metabolism. London: Churchill Livingstone: 1973; p. 51-6.

Format for chapter references: Hudson FB, Hawcroft J. Duration of treatment in phenylketonuria. In: Seakins J, Saunders R, editors. Treatment of inborn errors of metabolism. London: Churchill Livingstone; 1973. p. 51-6.

Journal article on the Internet: Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. Am J Nurs [serial on the Internet]. 2002 Jun [cited 2002 Aug 12];102(6):[about 3 p.]. Available from: http://www.nursingworld.org/AJN/2002/june/Wawatch.htm

Illustrations. Illustrations should be numbered and provided with suitable legends.

A reasonable number of halftone illustrations or line drawings will be reproduced at no cost to the author, but special arrangements must be made with the Editor-in-Chief for color plates, elaborate tables, or extra illustrations. Typewritten or freehand lettering on illustrations is not acceptable. All lettering must be done professionally, and letters should be in proportion to the drawings or photographs on which they appears.

Illustrations must be submitted in electronic format. All images should be at least 5 inches wide. Images should be provided in TIF or EPS format, per the instruction for online submission at http://ees.elsevier.com/tripleo . Macintosh or PC is acceptable. Graphics software such as Photoshop and Illustrator (not presentation software such as PowerPoint, CorelDraw, or Harvard Graphics) should be used in the creation of the art. Color images need to be CMYK, at least 300 DPI, and be accompanied by a digital color proof, not a color laser print or color photocopy. Note: This proof will be used at press for color reproduction. Gray scale images should be at least 300 DPI accompanied by a proof. Combinations of gray scale and line art should be at least 1200 DPI accompanied by a proof. Line art (black and white or color) should be at least 1200 DPI with a proof.

For best possible reproduction, avoid using shading or dotted patterns; if unavoidable, submit this type of illustration in the form of a glossy photograph for best results. Use thick, solid lines and bold, solid type. Place lettering on a white background; avoid reverse type (white lettering on a dark background). Typewritten or freehand lettering is unacceptable. All lettering must be done professionally and should be in proportion to the drawing graph, or photograph. Do not send original art work, radiograph films, or electrocardiographic strips. Any special instructions regarding sizing should be clearly noted.

Legends to illustrations. Each illustration must be accompanied by a legend. These should be typed double-spaced on a separate page. If an illustration has been taken from published material, the legend must give full credit to the original source.

Tables. The tables should be typewritten double-spaced, including column heads, data and footnotes, and submitted on separate pages. Tables should be self-explanatory and should supplement, not duplicate, the text. All table reference citations should be repeats of numbers assigned within the text, not initial citations. A concise title should be supplied for each table. All columns should carry concise headings

describing the data therein. Type all footnotes immediately below the table and define abbreviations. If a table or any data therein have been previously published, a footnote to the table must give full credit to the original source.

Video and Computer Graphics. Authors are encouraged to submit videos and computer-generated graphics; eg, a slide presentation with or without animation and sound. An author who wishes to supply such material should notify the editors in the cover letter and note this intention in the Author Comments area of the online submission. Although the publisher will not edit any video or computer graphic, editors and reviewers may suggest changes. All patient-identifying information must be removed or masked.

The maximum length of a video or computer graphic is 8 minutes. Longer submissions may be divided into smaller clips, each of which should be identified at the beginning of the section (eg, Video Clip 1, Graphic 1). A concise legend for each video clip or computer graphic presentation must be included with the manuscript. Videos are to be submitted in MGEG-1 or MPEG-2 (*.mpg) or QuickTime (*.mov) format. More detailed instructions can be found at http://www.elsevier.com/artwork . Videos and computer graphics accompanying a manuscript declined for publication will not be accepted separately. If the manuscript is accepted for publication, the presentation will be archived at www.mosby.com/tripleo.

Permissions. Direct quotations, tables, or illustrations that have appeared in copyrighted material must be accompanied by **written permission** for their use from the copyright owner and original author along with complete information with respect to source. Photographs of identifiable persons must be accompanied by signed releases showing informed consent. Articles appear in both the print and online versions of the journal, and wording should specify permission in all forms and media. Failure to obtain electronic permission rights may result in the images not appearing in the the print or online versions.

NOTE: FOLLOW INSTRUCTIONS FOR ONLINE SUBMISSION AT HTTP://EES.ELSEVIER.COM/TRIPLEO

Announcements. Announcements must be received by the Editorial Office at least ten weeks before the desired month of publication. Items published at no charge include those received from a sponsoring society of the Journal; courses and conferences sponsored by state, regional, or national dental organizations; and programs for the dental profession sponsored by government agencies. All other announcements selected for publication by the Editor carry a charge of $60 US, and the fee must accompany the request to publish.

Reprints. Because of the extremely high cost of preparing color articles, author reprints for articles containing color illustrations have to be prepared as overprints (overrun pages). Order forms will be sent to the **corresponding author** of articles containing color illustrations, so that overprints of those articles can be ordered the month of publication. No complimentary overprints or reprints will be provided.

Checklist for authors

__Signed copyright transfer statement (signed by all authors) (FAXED to Editorial Office)
__Letter of submission
__Title page
    __Title of article
    __Full names(s), academic degree(s), affiliation(s) and titles of author(s)
    __Author to whom correspondence, galleys, and reprint request are to be sent, including address
    and business and home telephone numbers, fax number, and e-mail address
__Structured abstract (double-spaced)
__Article proper (double-spaced)
(Figures and tables should not be part of the text of the manuscript but added as separate files)
__Statement of IRB review (stated in manuscript)
__References (double-spaced on a separate page)
__Reprint requests line (on a separate page)
__Tables (double-spaced, on separate pages)
__Legends (double-spaced, on a separate page)
__Illustrations, properly formatted (as separate files)
__Video/computer graphics, properly formatted (as separate files)
__Acknowledgments (on a separate page)

__Source of funding for research (on a separate page)
__Signed permission to reproduce previously published material, in all forms and media (scanned in as a file)
__Signed permission to publish photographs of identifiable persons from the individual specifying permission in all forms and media (scanned in as a file)
__Financial interest disclosure, if applicable (on a separate page)
__If this paper was presented at a meeting identification of organization, city, and year (on a separate page)

Updated June 2008

APÊNDICES

APÊNDICES

Osso alveolar: regiões apical (1), vestibular (2), palatina (3) e inter-radicular (4) (HE; aumento aproximado de 40x).

Osteoclasto (seta) na lacuna de Howship. Grupo-controle, região apical (HE; aumento aproximado de 400X).

Osteoclastos (setas). Grupo alendronato, região apical (HE; aumento aproximado de 400x).

Osteoclasto (seta). Grupo ácido zoledrônico, região palatina (HE; aumento aproximado de 400x).

Osso alveolar. Grupo-controle, região apical (HE; aumento aproximado de 100x). **LP**: ligamento periodontal; **C**: cemento.

Osso alveolar. Grupo alendronato, região apical (HE; aumento aproximado de 100x). **LP**: ligamento periodontal; **C**: cemento.

Osso alveolar. Grupo ácido zoledrônico, região inter-radicular (HE; aumento aproximado de 100x). **LP**: ligamento periodontal; **D**: dentina.


Fibras colágenas nos espaços medulares do osso alveolar. Grupo-controle, região apical (picrossírius; aumento aproximado de 200x). **LP**:ligamento periodontal

Fibras colágenas nos espaços medulares do osso alveolar. Grupo alendronato, região apical (picrossírius; aumento aproximado de 200x).


Fibras colágenas nos espaços medulares do osso alveolar. Grupo ácido zoledrônico, região vestibular (picrossírius; aumento aproximado de 100x). **LP**: ligamento periodontal; **C**: cemento; **D**: dentina.

Expressão de OPG no osso alveolar. Grupo-controle, região apical
(imunoistoquímica; aumento aproximado de 200x).

Expressão de OPG no osso alveolar. Grupo alendronato, região palatina
(imunoistoquímica; aumento aproximado de 200x).

Expressão de OPG no osso alveolar. Grupo ácido zoledrônico, região inter-radicular (imunoistoquímica; aumento aproximado de 200x).